The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.BLOOD_CHEMISTRY | Observations: | 19055 |
| Member Type: | DATA | Variables: | 28 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 18 | ALBUMIN | Num | 8 | 184 | | | ALBUMIN |
| 20 | ALT | Num | 8 | 200 | | | ALT |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 19 | AST | Num | 8 | 192 | | | AST |
| 16 | BUN | Num | 8 | 168 | | | BUN |
| 26 | CHOLESTEROL | Num | 8 | 248 | | | CHOLESTEROL |
| 25 | CK | Num | 8 | 240 | | | CK |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 17 | CREATININE | Num | 8 | 176 | | | CREATININE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 22 | DIRECT_BILIRUBIN | Num | 8 | 216 | | | DIRECT_BILIRUBIN |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 15 | GLUCOSE | Num | 8 | 160 | | | GLUCOSE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 14 | LAB_CODE | Num | 8 | 152 | | | LAB_CODE |
| 24 | LIPASE | Num | 8 | 232 | | | LIPASE |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 28 | PREGNANCY_TEST | Num | 8 | 264 | | | PREGNANCY_TEST |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 23 | SERUM_AMYLASE | Num | 8 | 224 | | | SERUM_AMYLASE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 21 | TOTAL_BILIRUBIN | Num | 8 | 208 | | | TOTAL_BILIRUBIN |
| 27 | TRIGLYCERIDES | Num | 8 | 256 | | | TRIGLYCERIDES |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.CHEMISTRY_IMMUNOLOGY | Observations: | 93166 |
| Member Type: | DATA | Variables: | 47 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 27 | AG_RATIO | Num | 8 | 256 | | | AG_RATIO |
| 25 | ALBUMIN | Num | 8 | 240 | | | ALBUMIN |
| 28 | ALK_PHOS | Num | 8 | 264 | | | ALK_PHOS |
| 33 | ALT | Num | 8 | 304 | | | ALT |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 29 | AST | Num | 8 | 272 | | | AST |
| 47 | BETA_2_ MICROGLOBULIN | Num | 8 | 416 | | | BETA_2_ MICROGLOBULIN |
| 16 | BUN | Num | 8 | 168 | | | BUN |
| 22 | CALCIUM | Num | 8 | 216 | | | CALCIUM |
| 20 | CHLORIDE | Num | 8 | 200 | | | CHLORIDE |
| 38 | CHOLESTEROL | Num | 8 | 344 | | | CHOLESTEROL |
| 37 | CK | Num | 8 | 336 | | | CK |
| 21 | CO2 | Num | 8 | 208 | | | CO2 |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 17 | CREATININE | Num | 8 | 176 | | | CREATININE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 32 | DIRECT_BILIRUBIN | Num | 8 | 296 | | | DIRECT_BILIRUBIN |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 34 | GGT | Num | 8 | 312 | | | GGT |
| 26 | GLOBULIN | Num | 8 | 248 | | | GLOBULIN |
| 15 | GLUCOSE | Num | 8 | 160 | | | GLUCOSE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 43 | IGA | Num | 8 | 384 | | | IGA |
| 45 | IGD | Num | 8 | 400 | | | IGD |
| 46 | IGE | Num | 8 | 408 | | | IGE |
| 42 | IGG | Num | 8 | 376 | | | IGG |
| 44 | IGM | Num | 8 | 392 | | | IGM |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 14 | LAB_CODE | Num | 8 | 152 | | | LAB_CODE |
| 30 | LDH | Num | 8 | 280 | | | LDH |
| 36 | LIPASE | Num | 8 | 328 | | | LIPASE |
| 23 | PHOSPHATE | Num | 8 | 224 | | | PHOSPHATE |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 19 | POTASSIUM | Num | 8 | 192 | | | POTASSIUM |

The SAS System

The CONTENTS Procedure

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 41 | PREGNANCY_TEST | Num | 8 | 368 | | | PREGNANCY_TEST |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 35 | SERUM_AMYLASE | Num | 8 | 320 | | | SERUM_AMYLASE |
| 18 | SODIUM | Num | 8 | 184 | | | SODIUM |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 31 | TOTAL_BILIRUBIN | Num | 8 | 288 | | | TOTAL_BILIRUBIN |
| 24 | TOTAL_PROTEIN | Num | 8 | 232 | | | TOTAL_PROTEIN |
| 39 | TRIGLYCERIDES | Num | 8 | 352 | | | TRIGLYCERIDES |
| 40 | URIC_ACID | Num | 8 | 360 | | | URIC_ACID |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.DEATH_SUMMARY | Observations: | 2890 |
| Member Type: | DATA | Variables: | 27 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 24 | AIDS_DEFINING | Num | 8 | 280 | | | AIDS_DEFINING |
| 17 | AIDS_HIV_RELATED | Num | 8 | 176 | | | AIDS_HIV_RELATED |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 18 | AUTOPSY_RPT_ AVAILABLE | Num | 8 | 184 | | | AUTOPSY_RPT_ AVAILABLE |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 20 | DEATH_CERT_ AVAILABLE | Num | 8 | 200 | | | DEATH_CERT_ AVAILABLE |
| 14 | DEATH_DATE | Num | 8 | 152 | DATETIME20. | DATETIME20. | DEATH_DATE |
| 15 | DEATH_DATE_PMDAYS | Num | 8 | 160 | | | DEATH_DATE_PMDAYS |
| 16 | DEATH_DATE_SOURCE | Num | 8 | 168 | | | DEATH_DATE_SOURCE |
| 19 | DEATH_NARR_ AVAILABLE | Num | 8 | 192 | | | DEATH_NARR_ AVAILABLE |
| 22 | DX_CODE | Num | 8 | 216 | | | DX_CODE |
| 23 | DX_CODE_T | Char | 50 | 224 | $50. | $50. | DX_CODE_T |
| 21 | DX_RATING | Num | 8 | 208 | | | DX_RATING |
| 27 | DX_SOURCE | Num | 8 | 400 | | | DX_SOURCE |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 25 | LOCUS | Char | 50 | 288 | $50. | $50. | LOCUS |
| 26 | METHOD | Char | 50 | 344 | $50. | $50. | METHOD |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.DEMOGRAPHY | Observations: | 19009 |
| Member Type: | DATA | Variables: | 54 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 49 | BIO_CHILDREN_NUMBER | Num | 8 | 2144 | | | BIO_CHILDREN_ NUMBER |
| 50 | BIO_CHILD_ BIRTH_DATE | Num | 8 | 2152 | DATETIME20. | DATETIME20. | BIO_CHILD_ BIRTH_DATE |
| 51 | BIO_CHILD_BIRTH_ DATE_T | Char | 50 | 2160 | $50. | $50. | BIO_CHILD_BIRTH_ DATE_T |
| 14 | BIRTH_CITY | Char | 50 | 152 | $50. | $50. | BIRTH_CITY |
| 16 | BIRTH_COUNTRY | Char | 50 | 264 | $50. | $50. | BIRTH_COUNTRY |
| 17 | BIRTH_DATE | Num | 8 | 320 | DATETIME20. | DATETIME20. | BIRTH_DATE |
| 15 | BIRTH_STATE | Char | 50 | 208 | $50. | $50. | BIRTH_STATE |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 43 | CURRENT_DUTY_STATUS | Num | 8 | 1952 | | | CURRENT_DUTY_ STATUS |
| 44 | CURRENT_DUTY_ STATUS_T | Char | 50 | 1960 | $50. | $50. | CURRENT_DUTY_ STATUS_T |
| 48 | CURRENT_MARITAL_ STATUS | Num | 8 | 2136 | | | CURRENT_MARITAL_ STATUS |
| 47 | CURRENT_RESIDENCE_ ZIP | Char | 50 | 2080 | $50. | $50. | CURRENT_RESIDENCE_ ZIP |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 22 | DOC_NEG_DATE | Num | 8 | 408 | DATETIME20. | DATETIME20. | DOC_NEG_DATE |
| 23 | DOC_NEG_DATE_SOURCE | Char | 50 | 416 | $50. | $50. | DOC_NEG_DATE_ SOURCE |
| 29 | DOC_POS_DATE | Num | 8 | 1056 | DATETIME20. | DATETIME20. | DOC_POS_DATE |
| 30 | DOC_POS_DATE_SOURCE | Char | 50 | 1064 | $50. | $50. | DOC_POS_DATE_ SOURCE |
| 31 | DOC_POS_LOCATION | Char | 50 | 1120 | $50. | $50. | DOC_POS_LOCATION |
| 32 | DOC_POS_METHOD | Num | 8 | 1176 | | | DOC_POS_METHOD |
| 46 | DUTY_STATION_ZIP | Char | 50 | 2024 | $50. | $50. | DUTY_STATION_ZIP |
| 40 | DUTY_STATUS_AT_DX | Num | 8 | 1832 | | | DUTY_STATUS_AT_DX |
| 41 | DUTY_STATUS_AT_DX_T | Char | 50 | 1840 | $50. | $50. | DUTY_STATUS_ AT_DX_T |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 21 | EVER_TESTED_NEG | Num | 8 | 400 | | | EVER_TESTED_NEG |

The SAS System

The CONTENTS Procedure

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 28 | EVER_TESTED_POS | Num | 8 | 1048 | | | EVER_TESTED_POS |
| 18 | GENDER | Num | 8 | 328 | | | GENDER |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 52 | PRIMARY_HIV_ PHYSICIAN | Char | 50 | 2216 | $50. | $50. | PRIMARY_HIV_ PHYSICIAN |
| 42 | PRIMARY_MIL_ JOB_AT_DX | Char | 50 | 1896 | $50. | $50. | PRIMARY_MIL_ JOB_AT_DX |
| 53 | PRIMARY_PHYS_ MIL_STATUS | Num | 8 | 2272 | | | PRIMARY_PHYS_ MIL_STATUS |
| 54 | PROTOCOL_ COORDINATOR | Num | 8 | 2280 | | | PROTOCOL_ COORDINATOR |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 19 | RACE_ETHNICITY | Num | 8 | 336 | | | RACE_ETHNICITY |
| 20 | RACE_ETHNICITY_T | Char | 50 | 344 | $50. | $50. | RACE_ETHNICITY_T |
| 45 | RANK | Num | 8 | 2016 | | | RANK |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 38 | SERVICE_AFFILIATION | Num | 8 | 1768 | | | SERVICE_ AFFILIATION |
| 39 | SERVICE_ AFFILIATION_T | Char | 50 | 1776 | $50. | $50. | SERVICE_ AFFILIATION_T |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 24 | UNDOC_NEG_DATE | Num | 8 | 472 | DATETIME20. | DATETIME20. | UNDOC_NEG_DATE |
| 25 | UNDOC_NEG_DATE_ PMDAYS | Num | 8 | 480 | | | UNDOC_NEG_DATE_ PMDAYS |
| 26 | UNDOC_NEG_LOCATION | Char | 500 | 488 | $500. | $500. | UNDOC_NEG_LOCATION |
| 33 | UNDOC_POS_DATE | Num | 8 | 1184 | DATETIME20. | DATETIME20. | UNDOC_POS_DATE |
| 34 | UNDOC_POS_DATE_ PMDAYS | Num | 8 | 1192 | | | UNDOC_POS_DATE_ PMDAYS |
| 35 | UNDOC_POS_LOCATION | Char | 500 | 1200 | $500. | $500. | UNDOC_POS_LOCATION |
| 36 | UNDOC_POS_METHOD | Num | 8 | 1704 | | | UNDOC_POS_METHOD |
| 27 | WHO_PERF_UNDOC_NEG | Char | 50 | 992 | $50. | $50. | WHO_PERF_UNDOC_NEG |
| 37 | WHO_PERF_UNDOC_POS | Char | 50 | 1712 | $50. | $50. | WHO_PERF_UNDOC_POS |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.DRUG_ALLERGY | Observations: | 3302 |
| Member Type: | DATA | Variables: | 20 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 16 | ANAPHYLAXIS | Num | 8 | 216 | | | ANAPHYLAXIS |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 18 | DRUG_ALLERGY_DATE | Num | 8 | 280 | DATETIME20. | DATETIME20. | DRUG_ALLERGY_DATE |
| 19 | DRUG_ALLERGY_ DATE_PMDAYS | Num | 8 | 288 | | | DRUG_ALLERGY_ DATE_PMDAYS |
| 17 | DRUG_ALLERGY_OTHER | Char | 50 | 224 | $50. | $50. | DRUG_ALLERGY_OTHER |
| 20 | DRUG_ALLERGY_ RPT_METHOD | Char | 30 | 296 | $30. | $30. | DRUG_ALLERGY_ RPT_METHOD |
| 14 | DRUG_ALLERGY_TYPE | Char | 50 | 152 | $50. | $50. | DRUG_ALLERGY_TYPE |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 15 | RASH | Num | 8 | 208 | | | RASH |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.ENROLLMENT | Observations: | 5749 |
| Member Type: | DATA | Variables: | 20 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 14 | MET_INCLUSION_ CRITERIA | Num | 8 | 152 | | | MET_INCLUSION_ CRITERIA |
| 20 | NEG_CONSENT_DATE | Num | 8 | 248 | DATETIME20. | DATETIME20. | NEG_CONSENT_DATE |
| 19 | NEG_CONSENT_SIGNED | Num | 8 | 240 | | | NEG_CONSENT_SIGNED |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 16 | POS_CONSENT_DATE | Num | 8 | 168 | DATETIME20. | DATETIME20. | POS_CONSENT_DATE |
| 15 | POS_CONSENT_SIGNED | Num | 8 | 160 | | | POS_CONSENT_SIGNED |
| 17 | POS_SPOUSE | Num | 8 | 176 | | | POS_SPOUSE |
| 18 | POS_SPOUSE_PIN | Char | 50 | 184 | $50. | $50. | POS_SPOUSE_PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.EXPORT_INFO | Observations: | 2 |
| Member Type: | DATA | Variables: | 8 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 7 | CLEANLINESS_LEVEL | Num | 8 | 96 | 5. | 5. | CLEANLINESS_LEVEL |
| 6 | EXPORT_COMPLETED | Num | 8 | 88 | DATETIME20. | DATETIME20. | EXPORT_COMPLETED |
| 2 | EXPORT_DESCRIPTION | Char | 30 | 8 | $30. | $30. | EXPORT_DESCRIPTION |
| 5 | EXPORT_STARTED | Num | 8 | 80 | DATETIME20. | DATETIME20. | EXPORT_STARTED |
| 1 | EXPORT_TYPE | Num | 8 | 0 | 5. | 5. | EXPORT_TYPE |
| 4 | RECIPE | Num | 8 | 72 | 5. | 5. | RECIPE |
| 8 | TABLES_EXPORTED | Num | 8 | 104 | 5. | 5. | TABLES_EXPORTED |
| 3 | VISIT_TABLE_NAME | Char | 30 | 40 | $30. | $30. | VISIT_TABLE_NAME |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.EXTRA_CERT_VB | Observations: | 1895 |
| Member Type: | DATA | Variables: | 17 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 4 | ACTUAL_VISIT_DATE | Num | 8 | 48 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 10 | APPROVED_DATE | Num | 8 | 120 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 9 | APPROVED_ID | Num | 8 | 112 | 7. | 7. | APPROVED_ID |
| 12 | COMPONENT_ OCCURRENCE | Num | 8 | 136 | | | COMPONENT_ OCCURRENCE |
| 7 | DATE_COLLECTED | Num | 8 | 96 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 6 | EVENT_OCCURRENCE | Num | 8 | 88 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 8 | LABORATORY | Num | 8 | 104 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 5 | PROTOCOL_SITE_CODE | Char | 30 | 56 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 11 | STATUS | Num | 8 | 128 | 5. | 5. | STATUS |
| 17 | VB_BD | Char | 30 | 224 | $30. | $30. | VB_BD |
| 13 | VB_DATE | Num | 8 | 144 | DATETIME20. | DATETIME20. | VB_DATE |
| 15 | VB_QUAL | Char | 30 | 184 | $30. | $30. | VB_QUAL |
| 16 | VB_RES | Num | 8 | 216 | | | VB_RES |
| 14 | VB_TYPE | Char | 30 | 152 | $30. | $30. | VB_TYPE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.HEMATOLOGY | Observations: | 122791 |
| Member Type: | DATA | Variables: | 30 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 26 | EOSINOPHIL_MANUAL | Num | 8 | 248 | | | EOSINOPHIL_MANUAL |
| 25 | EOSINOPHIL_PERCENT | Num | 8 | 240 | | | EOSINOPHIL_PERCENT |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 16 | HEMOGLOBIN | Num | 8 | 168 | | | HEMOGLOBIN |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 14 | LAB_CODE | Num | 8 | 152 | | | LAB_CODE |
| 22 | LYMPHOCYTE_MANUAL | Num | 8 | 216 | | | LYMPHOCYTE_MANUAL |
| 21 | LYMPHOCYTE_PERCENT | Num | 8 | 208 | | | LYMPHOCYTE_PERCENT |
| 17 | MCV | Num | 8 | 176 | | | MCV |
| 24 | MONOCYTE_MANUAL | Num | 8 | 232 | | | MONOCYTE_MANUAL |
| 23 | MONOCYTE_PERCENT | Num | 8 | 224 | | | MONOCYTE_PERCENT |
| 20 | NEUTROPHIL_MANUAL | Num | 8 | 200 | | | NEUTROPHIL_MANUAL |
| 19 | NEUTROPHIL_PERCENT | Num | 8 | 192 | | | NEUTROPHIL_PERCENT |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 18 | PLATELET_COUNT | Num | 8 | 184 | | | PLATELET_COUNT |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 29 | PT | Num | 8 | 272 | | | PT |
| 30 | PTT | Num | 8 | 280 | | | PTT |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 27 | RETICULOCYTE_COUNT | Num | 8 | 256 | | | RETICULOCYTE_COUNT |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 15 | WBC | Num | 8 | 160 | | | WBC |
| 28 | WESTERGREN_ESR | Num | 8 | 264 | | | WESTERGREN_ESR |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.HIV_SUBTYPE | Observations: | 725 |
| Member Type: | DATA | Variables: | 25 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 15 | EIA_SUBTYPE | Num | 8 | 160 | | | EIA_SUBTYPE |
| 16 | EIA_SUBTYPE_T | Char | 50 | 168 | $50. | $50. | EIA_SUBTYPE_T |
| 14 | EIA_TEST_DATE | Num | 8 | 152 | DATETIME20. | DATETIME20. | EIA_TEST_DATE |
| 18 | ENV_SUBTYPE | Num | 8 | 232 | | | ENV_SUBTYPE |
| 19 | ENV_SUBTYPE_T | Char | 50 | 240 | $50. | $50. | ENV_SUBTYPE_T |
| 17 | ENV_TEST_DATE | Num | 8 | 224 | DATETIME20. | DATETIME20. | ENV_TEST_DATE |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 24 | FULL_SUBTYPE | Num | 8 | 376 | | | FULL_SUBTYPE |
| 25 | FULL_SUBTYPE_T | Char | 50 | 384 | $50. | $50. | FULL_SUBTYPE_T |
| 23 | FULL_TEST_DATE | Num | 8 | 368 | DATETIME20. | DATETIME20. | FULL_TEST_DATE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 21 | POL_SUBTYPE | Num | 8 | 304 | | | POL_SUBTYPE |
| 22 | POL_SUBTYPE_T | Char | 50 | 312 | $50. | $50. | POL_SUBTYPE_T |
| 20 | POL_TEST_DATE | Num | 8 | 296 | DATETIME20. | DATETIME20. | POL_TEST_DATE |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.HOSPITALIZATION | Observations: | 1589 |
| Member Type: | DATA | Variables: | 21 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 18 | ADMISSION_DATE | Num | 8 | 1224 | DATETIME20. | DATETIME20. | ADMISSION_DATE |
| 19 | ADMISSION_DATE_PMDAYS | Num | 8 | 1232 | | | ADMISSION_DATE_PMDAYS |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_OCCURRENCE | Num | 8 | 144 | | | COMPONENT_OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 20 | DISCHARGE_DATE | Num | 8 | 1240 | DATETIME20. | DATETIME20. | DISCHARGE_DATE |
| 21 | DISCHARGE_DATE_PMDAYS | Num | 8 | 1248 | | | DISCHARGE_DATE_PMDAYS |
| 15 | DX_COMMENT | Char | 500 | 160 | $500. | $500. | DX_COMMENT |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 17 | HOSPITAL_LOCATION | Char | 500 | 720 | $500. | $500. | HOSPITAL_LOCATION |
| 16 | HOSPITAL_NAME | Char | 50 | 664 | $50. | $50. | HOSPITAL_NAME |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 14 | PRIMARY_DISCHARGE_DX | Num | 8 | 152 | | | PRIMARY_DISCHARGE_DX |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.IMMUNIZATION | Observations: | 17694 |
| Member Type: | DATA | Variables: | 17 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 14 | IMMUNIZATION_CODE | Num | 8 | 152 | | | IMMUNIZATION_CODE |
| 15 | IMMUNIZATION_DATE | Num | 8 | 160 | DATETIME20. | DATETIME20. | IMMUNIZATION_DATE |
| 16 | IMMUNIZATION_ DATE_PMDAYS | Num | 8 | 168 | | | IMMUNIZATION_ DATE_PMDAYS |
| 17 | IMMUNIZATION_ RPT_METHOD | Char | 30 | 176 | $30. | $30. | IMMUNIZATION_ RPT_METHOD |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.LYMPHOCYTE_PROFILE | Observations: | 74642 |
| Member Type: | DATA | Variables: | 24 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 23 | CD19_PERCENT | Num | 8 | 224 | | | CD19_PERCENT |
| 18 | CD3_PERCENT | Num | 8 | 184 | | | CD3_PERCENT |
| 20 | CD4_COUNT | Num | 8 | 200 | | | CD4_COUNT |
| 19 | CD4_PERCENT | Num | 8 | 192 | | | CD4_PERCENT |
| 24 | CD56_PERCENT | Num | 8 | 232 | | | CD56_PERCENT |
| 22 | CD8_COUNT | Num | 8 | 216 | | | CD8_COUNT |
| 21 | CD8_PERCENT | Num | 8 | 208 | | | CD8_PERCENT |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 14 | LAB_CODE | Num | 8 | 152 | | | LAB_CODE |
| 17 | LYMPH_COUNT | Num | 8 | 176 | | | LYMPH_COUNT |
| 16 | LYMPH_PERCENT | Num | 8 | 168 | | | LYMPH_PERCENT |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 15 | WBC | Num | 8 | 160 | | | WBC |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.MEDICAL_HISTORY | Observations: | 73755 |
| Member Type: | DATA | Variables: | 22 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 15 | AIDS_DEFINING | Num | 8 | 160 | | | AIDS_DEFINING |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 14 | DX_CODE | Num | 8 | 152 | | | DX_CODE |
| 22 | DX_COMMENT | Char | 500 | 312 | $500. | $500. | DX_COMMENT |
| 18 | DX_END_DATE | Num | 8 | 184 | DATETIME20. | DATETIME20. | DX_END_DATE |
| 19 | DX_END_DATE_PMDAYS | Num | 8 | 192 | | | DX_END_DATE_PMDAYS |
| 16 | DX_START_DATE | Num | 8 | 168 | DATETIME20. | DATETIME20. | DX_START_DATE |
| 17 | DX_START_DATE_ PMDAYS | Num | 8 | 176 | | | DX_START_DATE_ PMDAYS |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 20 | LOCUS | Char | 50 | 200 | $50. | $50. | LOCUS |
| 21 | METHOD | Char | 50 | 256 | $50. | $50. | METHOD |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.MEDICATION | Observations: | 85356 |
| Member Type: | DATA | Variables: | 24 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 14 | DRUG_CODE | Num | 8 | 152 | | | DRUG_CODE |
| 15 | DRUG_CODE_T | Char | 50 | 160 | $50. | $50. | DRUG_CODE_T |
| 16 | DRUG_START_DATE | Num | 8 | 216 | DATETIME20. | DATETIME20. | DRUG_START_DATE |
| 17 | DRUG_START_ DATE_PMDAYS | Num | 8 | 224 | | | DRUG_START_ DATE_PMDAYS |
| 18 | DRUG_STOP_DATE | Num | 8 | 232 | DATETIME20. | DATETIME20. | DRUG_STOP_DATE |
| 19 | DRUG_STOP_DATE_ PMDAYS | Num | 8 | 240 | | | DRUG_STOP_DATE_ PMDAYS |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 23 | INDICATION | Num | 8 | 320 | | | INDICATION |
| 24 | INDICATION_T | Char | 50 | 328 | $50. | $50. | INDICATION_T |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 20 | ROUTE | Num | 8 | 248 | | | ROUTE |
| 21 | ROUTE_T | Char | 50 | 256 | $50. | $50. | ROUTE_T |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 22 | THERAPY_INTENT | Num | 8 | 312 | | | THERAPY_INTENT |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.MISC_EXAM | Observations: | 31105 |
| Member Type: | DATA | Variables: | 22 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 16 | ARMED_FORCES_STAGE | Num | 8 | 168 | | | ARMED_FORCES_STAGE |
| 17 | BLOOD_SAMPLE_ COLLECTED | Num | 8 | 176 | | | BLOOD_SAMPLE_ COLLECTED |
| 18 | BLOOD_SAMPLE_ COLLECTED_T | Char | 50 | 184 | $50. | $50. | BLOOD_SAMPLE_ COLLECTED_T |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 22 | DAYS_MISSED_DRUG_ REACTION | Num | 8 | 264 | | | DAYS_MISSED_DRUG_ REACTION |
| 21 | DAYS_MISSED_ MED_RELATED | Num | 8 | 256 | | | DAYS_MISSED_ MED_RELATED |
| 20 | DAYS_MISSED_TOTAL | Num | 8 | 248 | | | DAYS_MISSED_TOTAL |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 14 | HEIGHT | Num | 8 | 152 | | | HEIGHT |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 15 | WEIGHT | Num | 8 | 160 | | | WEIGHT |
| 19 | WORK_IN_LAST_ 6_MONTHS | Num | 8 | 240 | | | WORK_IN_LAST_ 6_MONTHS |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.MISC_FINDINGS | Observations: | 45493 |
| Member Type: | DATA | Variables: | 20 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 15 | DTH_SKIN_TEST_DATE | Num | 8 | 184 | DATETIME20. | DATETIME20. | DTH_SKIN_TEST_DATE |
| 14 | DTH_SKIN_TEST_ RESULT | Char | 30 | 152 | $30. | $30. | DTH_SKIN_TEST_ RESULT |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 19 | LYMPHADENOPATHY | Num | 8 | 240 | | | LYMPHADENOPATHY |
| 20 | LYMPHADENOPATHY_ DATE | Num | 8 | 248 | DATETIME20. | DATETIME20. | LYMPHADENOPATHY_ DATE |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 18 | PPD_DATE | Num | 8 | 232 | DATETIME20. | DATETIME20. | PPD_DATE |
| 16 | PPD_DIAMETER | Num | 8 | 192 | | | PPD_DIAMETER |
| 17 | PPD_RESULT | Char | 30 | 200 | $30. | $30. | PPD_RESULT |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.NONB_SCREENING | Observations: | 1603 |
| Member Type: | DATA | Variables: | 22 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 20 | AFRICA | Num | 8 | 200 | | | AFRICA |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 15 | CANADA_MEXICO | Num | 8 | 160 | | | CANADA_MEXICO |
| 16 | CARIBBEAN | Num | 8 | 168 | | | CARIBBEAN |
| 17 | CENT_SOUTH_AMER | Num | 8 | 176 | | | CENT_SOUTH_AMER |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 18 | EASTASIA_PACRIM | Num | 8 | 184 | | | EASTASIA_PACRIM |
| 22 | EAST_EUROPE | Num | 8 | 216 | | | EAST_EUROPE |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 14 | FOREIGN_EXP | Num | 8 | 152 | | | FOREIGN_EXP |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 19 | SE_ASIA_MIDEAST | Num | 8 | 192 | | | SE_ASIA_MIDEAST |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 21 | WEST_EUROPE | Num | 8 | 208 | | | WEST_EUROPE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_ALL_AF_STAGE | Observations: | 42742 |
| Member Type: | DATA | Variables: | 17 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 16 | ARMED_FORCES_STAGE | Num | 8 | 216 | | | ARMED_FORCES_STAGE |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 14 | SOURCE_TABLE | Char | 50 | 152 | $50. | $50. | SOURCE_TABLE |
| 17 | STAGE_CENTER | Num | 8 | 224 | | | STAGE_CENTER |
| 15 | STAGE_DATE | Num | 8 | 208 | DATETIME20. | DATETIME20. | STAGE_DATE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_ALL_BLOOD_CHEM_IMM | Observations: | 119856 |
| Member Type: | DATA | Variables: | 48 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 28 | AG_RATIO | Num | 8 | 288 | | | AG_RATIO |
| 26 | ALBUMIN | Num | 8 | 272 | | | ALBUMIN |
| 29 | ALK_PHOS | Num | 8 | 296 | | | ALK_PHOS |
| 34 | ALT | Num | 8 | 336 | | | ALT |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | | | APPROVED_ID |
| 30 | AST | Num | 8 | 304 | | | AST |
| 48 | BETA_2_ MICROGLOBULIN | Num | 8 | 448 | | | BETA_2_ MICROGLOBULIN |
| 17 | BUN | Num | 8 | 200 | | | BUN |
| 23 | CALCIUM | Num | 8 | 248 | | | CALCIUM |
| 21 | CHLORIDE | Num | 8 | 232 | | | CHLORIDE |
| 39 | CHOLESTEROL | Num | 8 | 376 | | | CHOLESTEROL |
| 38 | CK | Num | 8 | 368 | | | CK |
| 22 | CO2 | Num | 8 | 240 | | | CO2 |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 18 | CREATININE | Num | 8 | 208 | | | CREATININE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 33 | DIRECT_BILIRUBIN | Num | 8 | 328 | | | DIRECT_BILIRUBIN |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 35 | GGT | Num | 8 | 344 | | | GGT |
| 27 | GLOBULIN | Num | 8 | 280 | | | GLOBULIN |
| 16 | GLUCOSE | Num | 8 | 192 | | | GLUCOSE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 44 | IGA | Num | 8 | 416 | | | IGA |
| 46 | IGD | Num | 8 | 432 | | | IGD |
| 47 | IGE | Num | 8 | 440 | | | IGE |
| 43 | IGG | Num | 8 | 408 | | | IGG |
| 45 | IGM | Num | 8 | 424 | | | IGM |
| 9 | LABORATORY | Num | 8 | 112 | | | LABORATORY |
| 15 | LAB_CODE | Num | 8 | 184 | | | LAB_CODE |
| 31 | LDH | Num | 8 | 312 | | | LDH |
| 37 | LIPASE | Num | 8 | 360 | | | LIPASE |
| 24 | PHOSPHATE | Num | 8 | 256 | | | PHOSPHATE |
| 2 | PIN | Num | 8 | 8 | | | PIN |
| 20 | POTASSIUM | Num | 8 | 224 | | | POTASSIUM |

The SAS System

The CONTENTS Procedure

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 42 | PREGNANCY_TEST | Num | 8 | 400 | | | PREGNANCY_TEST |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | | | RECIPE |
| 36 | SERUM_AMYLASE | Num | 8 | 352 | | | SERUM_AMYLASE |
| 19 | SODIUM | Num | 8 | 216 | | | SODIUM |
| 14 | SOURCE_TABLE | Char | 30 | 152 | $30. | $30. | SOURCE_TABLE |
| 12 | STATUS | Num | 8 | 136 | | | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | | | STUDY_DAY |
| 32 | TOTAL_BILIRUBIN | Num | 8 | 320 | | | TOTAL_BILIRUBIN |
| 25 | TOTAL_PROTEIN | Num | 8 | 264 | | | TOTAL_PROTEIN |
| 40 | TRIGLYCERIDES | Num | 8 | 384 | | | TRIGLYCERIDES |
| 41 | URIC_ACID | Num | 8 | 392 | | | URIC_ACID |

The SAS System

The CONTENTS Procedure

```
Data Set Name: NH.POST_BIO_CHILDREN          Observations:         2820
Member Type:   DATA                          Variables:            4
Engine:        ORACLE                        Indexes:              0
Created:       .                             Observation Length:   0
Last Modified: .                             Deleted Observations: 0
Protection:                                  Compressed:           NO
Data Set Type:                               Sorted:               NO
Label:
```

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 4 | BIRTH_DATE_PMDAYS | Char | 30 | 24 | $30. | $30. | BIRTH_DATE_PMDAYS |
| 3 | CHILD_BIRTH_DATE | Num | 8 | 16 | DATETIME20. | DATETIME20. | CHILD_BIRTH_DATE |
| 2 | CHILD_NUMBER | Num | 8 | 8 | 4. | 4. | CHILD_NUMBER |
| 1 | PIN | Num | 8 | 0 | 7. | 7. | PIN |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_CLINICAL_RESULTS | Observations: | 100895 |
| Member Type: | DATA | Variables: | 13 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 4 | ARMED_FORCES_STAGE | Num | 8 | 48 | 5. | 5. | ARMED_FORCES_STAGE |
| 7 | BELOW_DETECTION | Char | 1 | 72 | $1. | $1. | BELOW_DETECTION |
| 10 | CD4_COUNT | Num | 8 | 144 | | | CD4_COUNT |
| 11 | CD4_PERCENT | Num | 8 | 152 | | | CD4_PERCENT |
| 12 | CD8_COUNT | Num | 8 | 160 | | | CD8_COUNT |
| 13 | CD8_PERCENT | Num | 8 | 168 | | | CD8_PERCENT |
| 3 | DATE_COLLECTED | Num | 8 | 40 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 1 | PIN | Num | 8 | 0 | 7. | 7. | PIN |
| 2 | PROTOCOL_SITE_CODE | Char | 30 | 8 | $30. | $30. | PROTOCOL_SITE_CODE |
| 8 | VB_ASSAY | Num | 8 | 80 | 3. | 3. | VB_ASSAY |
| 9 | VB_ASSAY_T | Char | 50 | 88 | $50. | $50. | VB_ASSAY_T |
| 5 | VB_COPIES | Num | 8 | 56 | | | VB_COPIES |
| 6 | VB_QUALIFIER | Char | 1 | 64 | $1. | $1. | VB_QUALIFIER |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_CURRENT_DEMOGRAPHY | Observations: | 4655 |
| Member Type: | DATA | Variables: | 59 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 49 | BIO_CHILDREN_NUMBER | Num | 8 | 2240 | | | BIO_CHILDREN_ NUMBER |
| 14 | BIRTH_CITY | Char | 50 | 152 | $50. | $50. | BIRTH_CITY |
| 16 | BIRTH_COUNTRY | Char | 50 | 264 | $50. | $50. | BIRTH_COUNTRY |
| 17 | BIRTH_DATE | Num | 8 | 320 | DATETIME20. | DATETIME20. | BIRTH_DATE |
| 15 | BIRTH_STATE | Char | 50 | 208 | $50. | $50. | BIRTH_STATE |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 43 | CURRENT_DUTY_STATUS | Num | 8 | 2048 | | | CURRENT_DUTY_ STATUS |
| 44 | CURRENT_DUTY_ STATUS_T | Char | 50 | 2056 | $50. | $50. | CURRENT_DUTY_ STATUS_T |
| 48 | CURRENT_MARITAL_ STATUS | Num | 8 | 2232 | | | CURRENT_MARITAL_ STATUS |
| 47 | CURRENT_RESIDENCE_ ZIP | Char | 50 | 2176 | $50. | $50. | CURRENT_RESIDENCE_ ZIP |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 22 | DOC_NEG_DATE | Num | 8 | 408 | DATETIME20. | DATETIME20. | DOC_NEG_DATE |
| 23 | DOC_NEG_DATE_SOURCE | Char | 50 | 416 | $50. | $50. | DOC_NEG_DATE_ SOURCE |
| 29 | DOC_POS_DATE | Num | 8 | 1056 | DATETIME20. | DATETIME20. | DOC_POS_DATE |
| 30 | DOC_POS_DATE_SOURCE | Char | 50 | 1064 | $50. | $50. | DOC_POS_DATE_ SOURCE |
| 31 | DOC_POS_LOCATION | Char | 50 | 1120 | $50. | $50. | DOC_POS_LOCATION |
| 32 | DOC_POS_METHOD | Char | 50 | 1176 | $50. | $50. | DOC_POS_METHOD |
| 46 | DUTY_STATION_ZIP | Char | 50 | 2120 | $50. | $50. | DUTY_STATION_ZIP |
| 40 | DUTY_STATUS_AT_DX | Num | 8 | 1928 | | | DUTY_STATUS_AT_DX |
| 41 | DUTY_STATUS_AT_DX_T | Char | 50 | 1936 | $50. | $50. | DUTY_STATUS_ AT_DX_T |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 21 | EVER_TESTED_NEG | Num | 8 | 400 | | | EVER_TESTED_NEG |
| 28 | EVER_TESTED_POS | Num | 8 | 1048 | | | EVER_TESTED_POS |
| 18 | GENDER | Num | 8 | 328 | | | GENDER |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |

The SAS System

The CONTENTS Procedure

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 58 | MILES_FROM_BAMC | Num | 8 | 2360 | | | MILES_FROM_BAMC |
| 57 | MILES_FROM_NMCP | Num | 8 | 2352 | | | MILES_FROM_NMCP |
| 56 | MILES_FROM_NMCSD | Num | 8 | 2344 | | | MILES_FROM_NMCSD |
| 54 | MILES_FROM_NNMC | Num | 8 | 2328 | | | MILES_FROM_NNMC |
| 59 | MILES_FROM_TAMC | Num | 8 | 2368 | | | MILES_FROM_TAMC |
| 55 | MILES_FROM_WHMC | Num | 8 | 2336 | | | MILES_FROM_WHMC |
| 53 | MILES_FROM_WRAMC | Num | 8 | 2320 | | | MILES_FROM_WRAMC |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 50 | PRIMARY_HIV_ PHYSICIAN | Char | 50 | 2248 | $50. | $50. | PRIMARY_HIV_ PHYSICIAN |
| 42 | PRIMARY_MIL_ JOB_AT_DX | Char | 50 | 1992 | $50. | $50. | PRIMARY_MIL_ JOB_AT_DX |
| 51 | PRIMARY_PHYS_ MIL_STATUS | Num | 8 | 2304 | | | PRIMARY_PHYS_ MIL_STATUS |
| 52 | PROTOCOL_ COORDINATOR | Num | 8 | 2312 | | | PROTOCOL_ COORDINATOR |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 19 | RACE_ETHNICITY | Num | 8 | 336 | | | RACE_ETHNICITY |
| 20 | RACE_ETHNICITY_T | Char | 50 | 344 | $50. | $50. | RACE_ETHNICITY_T |
| 45 | RANK | Num | 8 | 2112 | | | RANK |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 38 | SERVICE_AFFILIATION | Num | 8 | 1864 | | | SERVICE_ AFFILIATION |
| 39 | SERVICE_ AFFILIATION_T | Char | 50 | 1872 | $50. | $50. | SERVICE_ AFFILIATION_T |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 24 | UNDOC_NEG_DATE | Num | 8 | 472 | DATETIME20. | DATETIME20. | UNDOC_NEG_DATE |
| 25 | UNDOC_NEG_DATE_ PMDAYS | Num | 8 | 480 | | | UNDOC_NEG_DATE_ PMDAYS |
| 26 | UNDOC_NEG_LOCATION | Char | 500 | 488 | $500. | $500. | UNDOC_NEG_LOCATION |
| 33 | UNDOC_POS_DATE | Num | 8 | 1232 | DATETIME20. | DATETIME20. | UNDOC_POS_DATE |
| 34 | UNDOC_POS_DATE_ PMDAYS | Num | 8 | 1240 | | | UNDOC_POS_DATE_ PMDAYS |
| 35 | UNDOC_POS_LOCATION | Char | 500 | 1248 | $500. | $500. | UNDOC_POS_LOCATION |
| 36 | UNDOC_POS_METHOD | Char | 50 | 1752 | $50. | $50. | UNDOC_POS_METHOD |
| 27 | WHO_PERF_UNDOC_NEG | Char | 50 | 992 | $50. | $50. | WHO_PERF_UNDOC_NEG |
| 37 | WHO_PERF_UNDOC_POS | Char | 50 | 1808 | $50. | $50. | WHO_PERF_UNDOC_POS |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_DEMOGRAPHY | Observations: | 15768 |
| Member Type: | DATA | Variables: | 52 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 49 | BIO_CHILDREN_NUMBER | Num | 8 | 2240 | | | BIO_CHILDREN_ NUMBER |
| 14 | BIRTH_CITY | Char | 50 | 152 | $50. | $50. | BIRTH_CITY |
| 16 | BIRTH_COUNTRY | Char | 50 | 264 | $50. | $50. | BIRTH_COUNTRY |
| 17 | BIRTH_DATE | Num | 8 | 320 | DATETIME20. | DATETIME20. | BIRTH_DATE |
| 15 | BIRTH_STATE | Char | 50 | 208 | $50. | $50. | BIRTH_STATE |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 43 | CURRENT_DUTY_STATUS | Num | 8 | 2048 | | | CURRENT_DUTY_ STATUS |
| 44 | CURRENT_DUTY_ STATUS_T | Char | 50 | 2056 | $50. | $50. | CURRENT_DUTY_ STATUS_T |
| 48 | CURRENT_MARITAL_ STATUS | Num | 8 | 2232 | | | CURRENT_MARITAL_ STATUS |
| 47 | CURRENT_RESIDENCE_ ZIP | Char | 50 | 2176 | $50. | $50. | CURRENT_RESIDENCE_ ZIP |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 22 | DOC_NEG_DATE | Num | 8 | 408 | DATETIME20. | DATETIME20. | DOC_NEG_DATE |
| 23 | DOC_NEG_DATE_SOURCE | Char | 50 | 416 | $50. | $50. | DOC_NEG_DATE_ SOURCE |
| 29 | DOC_POS_DATE | Num | 8 | 1056 | DATETIME20. | DATETIME20. | DOC_POS_DATE |
| 30 | DOC_POS_DATE_SOURCE | Char | 50 | 1064 | $50. | $50. | DOC_POS_DATE_ SOURCE |
| 31 | DOC_POS_LOCATION | Char | 50 | 1120 | $50. | $50. | DOC_POS_LOCATION |
| 32 | DOC_POS_METHOD | Char | 50 | 1176 | $50. | $50. | DOC_POS_METHOD |
| 46 | DUTY_STATION_ZIP | Char | 50 | 2120 | $50. | $50. | DUTY_STATION_ZIP |
| 40 | DUTY_STATUS_AT_DX | Num | 8 | 1928 | | | DUTY_STATUS_AT_DX |
| 41 | DUTY_STATUS_AT_DX_T | Char | 50 | 1936 | $50. | $50. | DUTY_STATUS_ AT_DX_T |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 21 | EVER_TESTED_NEG | Num | 8 | 400 | | | EVER_TESTED_NEG |
| 28 | EVER_TESTED_POS | Num | 8 | 1048 | | | EVER_TESTED_POS |
| 18 | GENDER | Num | 8 | 328 | | | GENDER |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |

The SAS System

The CONTENTS Procedure

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 50 | PRIMARY_HIV_ PHYSICIAN | Char | 50 | 2248 | $50. | $50. | PRIMARY_HIV_ PHYSICIAN |
| 42 | PRIMARY_MIL_ JOB_AT_DX | Char | 50 | 1992 | $50. | $50. | PRIMARY_MIL_ JOB_AT_DX |
| 51 | PRIMARY_PHYS_ MIL_STATUS | Num | 8 | 2304 | | | PRIMARY_PHYS_ MIL_STATUS |
| 52 | PROTOCOL_ COORDINATOR | Num | 8 | 2312 | | | PROTOCOL_ COORDINATOR |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 19 | RACE_ETHNICITY | Num | 8 | 336 | | | RACE_ETHNICITY |
| 20 | RACE_ETHNICITY_T | Char | 50 | 344 | $50. | $50. | RACE_ETHNICITY_T |
| 45 | RANK | Num | 8 | 2112 | | | RANK |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 38 | SERVICE_AFFILIATION | Num | 8 | 1864 | | | SERVICE_ AFFILIATION |
| 39 | SERVICE_ AFFILIATION_T | Char | 50 | 1872 | $50. | $50. | SERVICE_ AFFILIATION_T |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 24 | UNDOC_NEG_DATE | Num | 8 | 472 | DATETIME20. | DATETIME20. | UNDOC_NEG_DATE |
| 25 | UNDOC_NEG_DATE_ PMDAYS | Num | 8 | 480 | | | UNDOC_NEG_DATE_ PMDAYS |
| 26 | UNDOC_NEG_LOCATION | Char | 500 | 488 | $500. | $500. | UNDOC_NEG_LOCATION |
| 33 | UNDOC_POS_DATE | Num | 8 | 1232 | DATETIME20. | DATETIME20. | UNDOC_POS_DATE |
| 34 | UNDOC_POS_DATE_ PMDAYS | Num | 8 | 1240 | | | UNDOC_POS_DATE_ PMDAYS |
| 35 | UNDOC_POS_LOCATION | Char | 500 | 1248 | $500. | $500. | UNDOC_POS_LOCATION |
| 36 | UNDOC_POS_METHOD | Char | 50 | 1752 | $50. | $50. | UNDOC_POS_METHOD |
| 27 | WHO_PERF_UNDOC_NEG | Char | 50 | 992 | $50. | $50. | WHO_PERF_UNDOC_NEG |
| 37 | WHO_PERF_UNDOC_POS | Char | 50 | 1808 | $50. | $50. | WHO_PERF_UNDOC_POS |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_DIAGNOSIS_CODE | Observations: | 148 |
| Member Type: | DATA | Variables: | 5 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | DIAGNOSIS_CODE | Num | 8 | 8 | 5. | 5. | DIAGNOSIS_CODE |
| 3 | DIAGNOSIS_CODE_CHECK | Char | 30 | 16 | $30. | $30. | DIAGNOSIS_CODE_CHECK |
| 4 | DIAGNOSIS_DESCRIPTION | Char | 255 | 48 | $255. | $255. | DIAGNOSIS_DESCRIPTION |
| 5 | DIAGNOSIS_TYPE | Char | 30 | 304 | $30. | $30. | DIAGNOSIS_TYPE |
| 1 | RECIPE | Num | 8 | 0 | | | RECIPE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_DRUG_CODE | Observations: | 492 |
| Member Type: | DATA | Variables: | 4 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | DRUG_CODE | Num | 8 | 8 | 5. | 5. | DRUG_CODE |
| 3 | DRUG_DESCRIPTION | Char | 100 | 16 | $100. | $100. | DRUG_DESCRIPTION |
| 4 | DRUG_TYPE | Char | 30 | 120 | $30. | $30. | DRUG_TYPE |
| 1 | RECIPE | Num | 8 | 0 | | | RECIPE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_DRUG_REGIMEN | Observations: | 17364 |
| Member Type: | DATA | Variables: | 35 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 10 | DRUG_REGIMEN | Char | 2000 | 72 | $2000. | $2000. | DRUG_REGIMEN |
| 9 | FI_COUNT | Num | 8 | 64 | 3. | 3. | FI_COUNT |
| 7 | NNRTI_COUNT | Num | 8 | 48 | 3. | 3. | NNRTI_COUNT |
| 6 | NRTI_COUNT | Num | 8 | 40 | 3. | 3. | NRTI_COUNT |
| 5 | NUMBER_OF_DRUGS | Num | 8 | 32 | 3. | 3. | NUMBER_OF_DRUGS |
| 15 | ON_3TC_YN | Char | 1 | 2104 | $1. | $1. | ON_3TC_YN |
| 16 | ON_ABV_YN | Char | 1 | 2112 | $1. | $1. | ON_ABV_YN |
| 17 | ON_ADV_YN | Char | 1 | 2120 | $1. | $1. | ON_ADV_YN |
| 29 | ON_AMV_YN | Char | 1 | 2216 | $1. | $1. | ON_AMV_YN |
| 31 | ON_ATV_YN | Char | 1 | 2232 | $1. | $1. | ON_ATV_YN |
| 11 | ON_AZT_YN | Char | 1 | 2072 | $1. | $1. | ON_AZT_YN |
| 14 | ON_D4T_YN | Char | 1 | 2096 | $1. | $1. | ON_D4T_YN |
| 13 | ON_DDC_YN | Char | 1 | 2088 | $1. | $1. | ON_DDC_YN |
| 12 | ON_DDI_YN | Char | 1 | 2080 | $1. | $1. | ON_DDI_YN |
| 22 | ON_DLV_YN | Char | 1 | 2160 | $1. | $1. | ON_DLV_YN |
| 23 | ON_EFV_YN | Char | 1 | 2168 | $1. | $1. | ON_EFV_YN |
| 20 | ON_FTC_YN | Char | 1 | 2144 | $1. | $1. | ON_FTC_YN |
| 34 | ON_HYD_YN | Char | 1 | 2256 | $1. | $1. | ON_HYD_YN |
| 27 | ON_IDV_YN | Char | 1 | 2200 | $1. | $1. | ON_IDV_YN |
| 35 | ON_IL2_YN | Char | 1 | 2264 | $1. | $1. | ON_IL2_YN |
| 24 | ON_INV_YN | Char | 1 | 2176 | $1. | $1. | ON_INV_YN |
| 33 | ON_LEX_YN | Char | 1 | 2248 | $1. | $1. | ON_LEX_YN |
| 30 | ON_LPV_YN | Char | 1 | 2224 | $1. | $1. | ON_LPV_YN |
| 28 | ON_NFV_YN | Char | 1 | 2208 | $1. | $1. | ON_NFV_YN |
| 21 | ON_NVP_YN | Char | 1 | 2152 | $1. | $1. | ON_NVP_YN |
| 19 | ON_PTF_YN | Char | 1 | 2136 | $1. | $1. | ON_PTF_YN |
| 26 | ON_RTV_YN | Char | 1 | 2192 | $1. | $1. | ON_RTV_YN |
| 25 | ON_SQV_YN | Char | 1 | 2184 | $1. | $1. | ON_SQV_YN |
| 18 | ON_TFV_YN | Char | 1 | 2128 | $1. | $1. | ON_TFV_YN |
| 32 | ON_TPV_YN | Char | 1 | 2240 | $1. | $1. | ON_TPV_YN |
| 1 | PIN | Num | 8 | 0 | 7. | 7. | PIN |
| 8 | PI_COUNT | Num | 8 | 56 | 3. | 3. | PI_COUNT |
| 2 | REGIMEN_NUMBER | Num | 8 | 8 | 5. | 5. | REGIMEN_NUMBER |
| 3 | REGIMEN_START_DATE | Num | 8 | 16 | DATETIME20. | DATETIME20. | REGIMEN_START_DATE |
| 4 | REGIMEN_STOP_DATE | Num | 8 | 24 | DATETIME20. | DATETIME20. | REGIMEN_STOP_DATE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_MEDICAL_HISTORY | Observations: | 73755 |
| Member Type: | DATA | Variables: | 23 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 15 | AIDS_DEFINING | Num | 8 | 160 | | | AIDS_DEFINING |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 14 | DX_CODE | Num | 8 | 152 | | | DX_CODE |
| 23 | DX_CODE_T | Char | 50 | 816 | $50. | $50. | DX_CODE_T |
| 22 | DX_COMMENT | Char | 500 | 312 | $500. | $500. | DX_COMMENT |
| 18 | DX_END_DATE | Num | 8 | 184 | DATETIME20. | DATETIME20. | DX_END_DATE |
| 19 | DX_END_DATE_PMDAYS | Num | 8 | 192 | | | DX_END_DATE_PMDAYS |
| 16 | DX_START_DATE | Num | 8 | 168 | DATETIME20. | DATETIME20. | DX_START_DATE |
| 17 | DX_START_DATE_ PMDAYS | Num | 8 | 176 | | | DX_START_DATE_ PMDAYS |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 20 | LOCUS | Char | 50 | 200 | $50. | $50. | LOCUS |
| 21 | METHOD | Char | 50 | 256 | $50. | $50. | METHOD |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_MEDICAL_HIST_SUMMARY | Observations: | 65114 |
| Member Type: | DATA | Variables: | 11 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 4 | AIDS_DEFINING | Num | 8 | 72 | | | AIDS_DEFINING |
| 2 | DX_CODE | Num | 8 | 8 | | | DX_CODE |
| 3 | DX_CODE_T | Char | 50 | 16 | $50. | $50. | DX_CODE_T |
| 7 | DX_END_DATE | Num | 8 | 96 | DATETIME20. | DATETIME20. | DX_END_DATE |
| 8 | DX_END_DATE_PMDAYS | Num | 8 | 104 | | | DX_END_DATE_PMDAYS |
| 9 | DX_RESOLVED | Char | 1 | 112 | $1. | $1. | DX_RESOLVED |
| 5 | DX_START_DATE | Num | 8 | 80 | DATETIME20. | DATETIME20. | DX_START_DATE |
| 6 | DX_START_DATE_ PMDAYS | Num | 8 | 88 | | | DX_START_DATE_ PMDAYS |
| 10 | LOCUS | Char | 50 | 120 | $50. | $50. | LOCUS |
| 11 | METHOD | Char | 50 | 176 | $50. | $50. | METHOD |
| 1 | PIN | Num | 8 | 0 | 7. | 7. | PIN |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_MEDICATION | Observations: | 80666 |
| Member Type: | DATA | Variables: | 24 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 14 | DRUG_CODE | Num | 8 | 152 | | | DRUG_CODE |
| 15 | DRUG_CODE_T | Char | 50 | 160 | $50. | $50. | DRUG_CODE_T |
| 16 | DRUG_START_DATE | Num | 8 | 216 | DATETIME20. | DATETIME20. | DRUG_START_DATE |
| 17 | DRUG_START_ DATE_PMDAYS | Num | 8 | 224 | | | DRUG_START_ DATE_PMDAYS |
| 18 | DRUG_STOP_DATE | Num | 8 | 232 | DATETIME20. | DATETIME20. | DRUG_STOP_DATE |
| 19 | DRUG_STOP_DATE_ PMDAYS | Num | 8 | 240 | | | DRUG_STOP_DATE_ PMDAYS |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 23 | INDICATION | Num | 8 | 320 | | | INDICATION |
| 24 | INDICATION_T | Char | 50 | 328 | $50. | $50. | INDICATION_T |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 20 | ROUTE | Num | 8 | 248 | | | ROUTE |
| 21 | ROUTE_T | Char | 50 | 256 | $50. | $50. | ROUTE_T |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 22 | THERAPY_INTENT | Num | 8 | 312 | | | THERAPY_INTENT |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_MEDICATION_SUMMARY | Observations: | 70066 |
| Member Type: | DATA | Variables: | 12 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | DRUG_CODE | Num | 8 | 8 | | | DRUG_CODE |
| 3 | DRUG_CODE_T | Char | 50 | 16 | $50. | $50. | DRUG_CODE_T |
| 4 | DRUG_START_DATE | Num | 8 | 72 | DATETIME20. | DATETIME20. | DRUG_START_DATE |
| 5 | DRUG_START_DATE_PMDAYS | Num | 8 | 80 | | | DRUG_START_DATE_PMDAYS |
| 6 | DRUG_STOP_DATE | Num | 8 | 88 | DATETIME20. | DATETIME20. | DRUG_STOP_DATE |
| 7 | DRUG_STOP_DATE_PMDAYS | Num | 8 | 96 | | | DRUG_STOP_DATE_PMDAYS |
| 11 | INDICATION | Num | 8 | 176 | | | INDICATION |
| 12 | INDICATION_T | Char | 50 | 184 | $50. | $50. | INDICATION_T |
| 1 | PIN | Num | 8 | 0 | 7. | 7. | PIN |
| 8 | ROUTE | Num | 8 | 104 | | | ROUTE |
| 9 | ROUTE_T | Char | 50 | 112 | $50. | $50. | ROUTE_T |
| 10 | THERAPY_INTENT | Num | 8 | 168 | | | THERAPY_INTENT |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.POST_SKIN_TEST_SUMMARY | Observations: | 9428 |
| Member Type: | DATA | Variables: | 6 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 1 | PIN | Num | 8 | 0 | 7. | 7. | PIN |
| 2 | SKIN_TEST_NUMBER | Num | 8 | 8 | 5. | 5. | SKIN_TEST_NUMBER |
| 4 | SKIN_TEST_OCCURRENCE | Num | 8 | 32 | 3. | 3. | SKIN_TEST_OCCURRENCE |
| 3 | SKIN_TEST_RESULT | Char | 10 | 16 | $10. | $10. | SKIN_TEST_RESULT |
| 5 | SKIN_TEST_START_DATE | Num | 8 | 40 | DATETIME20. | DATETIME20. | SKIN_TEST_START_DATE |
| 6 | SKIN_TEST_STOP_DATE | Num | 8 | 48 | DATETIME20. | DATETIME20. | SKIN_TEST_STOP_DATE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.PROTOCOL_CLEANLINESS | Observations: | 5 |
| Member Type: | DATA | Variables: | 2 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 1 | CLEANLINESS | Num | 8 | 0 | 3. | 3. | CLEANLINESS |
| 2 | DESCRIPTION | Char | 30 | 8 | $30. | $30. | DESCRIPTION |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.PROTOCOL_LABORATORY | Observations: | 1 |
| Member Type: | DATA | Variables: | 3 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 3 | FORMAL_LAB_NAME | Char | 50 | 40 | $50. | $50. | FORMAL_LAB_NAME |
| 1 | LABORATORY | Num | 8 | 0 | 5. | 5. | LABORATORY |
| 2 | PROTOCOL_LAB_NAME | Char | 30 | 8 | $30. | $30. | PROTOCOL_LAB_NAME |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.PROTOCOL_LOOKUP_CODES | Observations: | 1108 |
| Member Type: | DATA | Variables: | 9 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 3 | COMPONENT_CODE | Num | 8 | 40 | 5. | 5. | COMPONENT_CODE |
| 4 | COMPONENT_NAME | Char | 30 | 48 | $30. | $30. | COMPONENT_NAME |
| 8 | DEFAULT_YN | Char | 1 | 376 | $1. | $1. | DEFAULT_YN |
| 7 | ENTRY_LABEL | Char | 255 | 120 | $255. | $255. | ENTRY_LABEL |
| 1 | EVENT_CODE | Num | 8 | 0 | 5. | 5. | EVENT_CODE |
| 2 | EVENT_NAME | Char | 30 | 8 | $30. | $30. | EVENT_NAME |
| 5 | LOOKUP | Num | 8 | 80 | 5. | 5. | LOOKUP |
| 9 | RANKING | Num | 8 | 384 | 5. | 5. | RANKING |
| 6 | VALID_ENTRY | Char | 30 | 88 | $30. | $30. | VALID_ENTRY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.PROTOCOL_PERSON | Observations: | 62 |
| Member Type: | DATA | Variables: | 3 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 3 | FORMAL_PERSON_NAME | Char | 50 | 40 | $50. | $50. | FORMAL_PERSON_NAME |
| 1 | PERSON_ID | Num | 8 | 0 | 7. | 7. | PERSON_ID |
| 2 | PROTOCOL_PERSON_NAME | Char | 30 | 8 | $30. | $30. | PROTOCOL_PERSON_NAME |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.PROTOCOL_SITE | Observations: | 7 |
| Member Type: | DATA | Variables: | 4 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 4 | FORMAL_SITE_NAME | Char | 50 | 72 | $50. | $50. | FORMAL_SITE_NAME |
| 2 | PROTOCOL_SITE_CODE | Char | 30 | 8 | $30. | $30. | PROTOCOL_SITE_CODE |
| 3 | PROTOCOL_SITE_NAME | Char | 30 | 40 | $30. | $30. | PROTOCOL_SITE_NAME |
| 1 | RSS_SITE_CODE | Num | 8 | 0 | 5. | 5. | RSS_SITE_CODE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.PROTOCOL_STATUS | Observations: | 2 |
| Member Type: | DATA | Variables: | 2 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | DESCRIPTION | Char | 30 | 8 | $30. | $30. | DESCRIPTION |
| 1 | STATUS | Num | 8 | 0 | 5. | 5. | STATUS |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.PROTOCOL_USER | Observations: | 83 |
| Member Type: | DATA | Variables: | 2 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | SITE | Char | 30 | 32 | $30. | $30. | SITE |
| 1 | USERNAME | Char | 30 | 0 | $30. | $30. | USERNAME |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.QUALITY_OF_LIFE | Observations: | 12827 |
| Member Type: | DATA | Variables: | 18 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 14 | ACTIVITY | Num | 8 | 152 | | | ACTIVITY |
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 15 | DAILY_LIVING | Num | 8 | 160 | | | DAILY_LIVING |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 16 | HEALTH | Num | 8 | 168 | | | HEALTH |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 18 | OUTLOOK | Num | 8 | 184 | | | OUTLOOK |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 17 | SUPPORT | Num | 8 | 176 | | | SUPPORT |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.RECLASSIFICATION | Observations: | 4582 |
| Member Type: | DATA | Variables: | 20 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 13 | COMPONENT_OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 16 | ENROLLMENT_STATUS_ CHANGE | Num | 8 | 168 | | | ENROLLMENT_STATUS_ CHANGE |
| 17 | ENROLLMENT_STATUS_ CHANGE_T | Char | 50 | 176 | $50. | $50. | ENROLLMENT_STATUS_ CHANGE_T |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 15 | LAST_VISIT_DATE | Num | 8 | 160 | DATETIME20. | DATETIME20. | LAST_VISIT_DATE |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 20 | RECLASSIFICATION_ COMMENT | Char | 500 | 248 | $500. | $500. | RECLASSIFICATION_ COMMENT |
| 14 | RECLASSIFICATION_ DATE | Num | 8 | 152 | DATETIME20. | DATETIME20. | RECLASSIFICATION_ DATE |
| 19 | RENEWED_CONSENT_DATE | Num | 8 | 240 | DATETIME20. | DATETIME20. | RENEWED_CONSENT_ DATE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 18 | TRANSFER_TO_CENTER | Num | 8 | 232 | | | TRANSFER_TO_CENTER |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.SEROLOGY | Observations: | 39109 |
| Member Type: | DATA | Variables: | 35 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 23 | CMV_IGG | Num | 8 | 224 | | | CMV_IGG |
| 24 | CMV_IGM | Num | 8 | 232 | | | CMV_IGM |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 25 | EBNA | Num | 8 | 240 | | | EBNA |
| 27 | EBV_CAPSID_AB_IGG | Num | 8 | 256 | | | EBV_CAPSID_AB_IGG |
| 28 | EBV_CAPSID_AB_IGM | Num | 8 | 264 | | | EBV_CAPSID_AB_IGM |
| 26 | EBV_EARLY_AG | Num | 8 | 248 | | | EBV_EARLY_AG |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 30 | FTA_ABS | Num | 8 | 280 | | | FTA_ABS |
| 15 | HEP_A_VIRUS_AB_IGM | Num | 8 | 160 | | | HEP_A_VIRUS_AB_IGM |
| 14 | HEP_A_VIRUS_ AB_TOTAL | Num | 8 | 152 | | | HEP_A_VIRUS_ AB_TOTAL |
| 17 | HEP_B_CORE_AB_IGM | Num | 8 | 176 | | | HEP_B_CORE_AB_IGM |
| 16 | HEP_B_CORE_AB_TOTAL | Num | 8 | 168 | | | HEP_B_CORE_AB_TOTAL |
| 18 | HEP_B_E_AB | Num | 8 | 184 | | | HEP_B_E_AB |
| 20 | HEP_B_E_AG | Num | 8 | 200 | | | HEP_B_E_AG |
| 19 | HEP_B_SURFACE_AB | Num | 8 | 192 | | | HEP_B_SURFACE_AB |
| 21 | HEP_B_SURFACE_AG | Num | 8 | 208 | | | HEP_B_SURFACE_AG |
| 22 | HEP_C_VIRUS_AB | Num | 8 | 216 | | | HEP_C_VIRUS_AB |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 31 | MHA_TP | Num | 8 | 288 | | | MHA_TP |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 29 | RPR | Num | 8 | 272 | | | RPR |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 32 | SYPHILIS_ELISA | Num | 8 | 296 | | | SYPHILIS_ELISA |
| 34 | TOXOPLASMA_AB_IGG | Num | 8 | 312 | | | TOXOPLASMA_AB_IGG |
| 35 | TOXOPLASMA_AB_IGM | Num | 8 | 320 | | | TOXOPLASMA_AB_IGM |
| 33 | TOXOPLASMA_AB_TOTAL | Num | 8 | 304 | | | TOXOPLASMA_AB_TOTAL |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STAGING_HISTORY | Observations: | 31227 |
| Member Type: | DATA | Variables: | 17 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 16 | ARMED_FORCES_STAGE | Num | 8 | 168 | | | ARMED_FORCES_STAGE |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 14 | FIRST_HIV_EVAL | Num | 8 | 152 | | | FIRST_HIV_EVAL |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 17 | STAGE_CENTER | Num | 8 | 176 | | | STAGE_CENTER |
| 15 | STAGE_DATE | Num | 8 | 160 | DATETIME20. | DATETIME20. | STAGE_DATE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_BAMC_100_MILE_ZIPS | Observations: | 395 |
| Member Type: | DATA | Variables: | 5 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | CITY | Char | 50 | 8 | $50. | $50. | CITY |
| 5 | MILES_TO_SITE | Num | 8 | 80 | | | MILES_TO_SITE |
| 4 | POPULATION | Num | 8 | 72 | | | POPULATION |
| 3 | STATE | Char | 2 | 64 | $2. | $2. | STATE |
| 1 | ZIP_CODE | Char | 5 | 0 | $5. | $5. | ZIP_CODE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_DRUGLK | Observations: | 473 |
| Member Type: | DATA | Variables: | 2 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 1 | D1_DRUGCODE | Char | 3 | 0 | $3. | $3. | D1_DRUGCODE |
| 2 | D1_DRUGNAME | Char | 50 | 8 | $50. | $50. | D1_DRUGNAME |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_DRUG_GROUPS | Observations: | 110 |
| Member Type: | DATA | Variables: | 2 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 1 | DRCODE | Num | 8 | 0 | | | DRCODE |
| 2 | DRTYPE | Char | 30 | 8 | $30. | $30. | DRTYPE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_DRUG_SYNONYM | Observations: | 296 |
| Member Type: | DATA | Variables: | 2 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 1 | DRUG_CODE | Num | 8 | 0 | 4. | 4. | DRUG_CODE |
| 2 | DRUG_SYNONYM | Char | 50 | 8 | $50. | $50. | DRUG_SYNONYM |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_DX_GROUPS | Observations: | 110 |
| Member Type: | DATA | Variables: | 3 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 1 | DXCODE | Num | 8 | 0 | | | DXCODE |
| 2 | DXGROUP_NUMBER | Num | 8 | 8 | | | DXGROUP_NUMBER |
| 3 | DXTYPE | Char | 30 | 16 | $30. | $30. | DXTYPE |

The SAS System

The CONTENTS Procedure

```
Data Set Name: NH.STATIC_LOCUS          Observations:         43
Member Type:   DATA                     Variables:            2
Engine:        ORACLE                   Indexes:              0
Created:       .                        Observation Length:   0
Last Modified: .                        Deleted Observations: 0
Protection:                             Compressed:           NO
Data Set Type:                          Sorted:               NO
Label:
```

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 1 | DX_LOCUS | Num | 8 | 0 | | | DX_LOCUS |
| 2 | DX_LOCUS_DESCRIPTION | Char | 30 | 8 | $30. | $30. | DX_LOCUS_DESCRIPTION |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_MEDHISTLK1 | Observations: | 135 |
| Member Type: | DATA | Variables: | 8 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 3 | DL_CATEGORY | Num | 8 | 16 | 6. | 6. | DL_CATEGORY |
| 2 | DL_DXCHECK | Char | 3 | 8 | $3. | $3. | DL_DXCHECK |
| 1 | DL_DXCODE | Num | 8 | 0 | 6. | 6. | DL_DXCODE |
| 5 | DL_DXDESC | Char | 60 | 32 | $60. | $60. | DL_DXDESC |
| 6 | DL_DXNUM | Num | 8 | 96 | 6. | 6. | DL_DXNUM |
| 8 | DL_SECT_DESC | Char | 25 | 112 | $25. | $25. | DL_SECT_DESC |
| 7 | DL_SECT_NUM | Num | 8 | 104 | 6. | 6. | DL_SECT_NUM |
| 4 | DL_SEROLOGY | Num | 8 | 24 | 6. | 6. | DL_SEROLOGY |

The SAS System

The CONTENTS Procedure

```
Data Set Name: NH.STATIC_METHOD          Observations:         6
Member Type:   DATA                      Variables:            2
Engine:        ORACLE                    Indexes:              0
Created:       .                         Observation Length:   0
Last Modified: .                         Deleted Observations: 0
Protection:                              Compressed:           NO
Data Set Type:                           Sorted:               NO
Label:
```

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 1 | DX_METHOD | Char | 1 | 0 | $1. | $1. | DX_METHOD |
| 2 | DX_METHOD_DESCRIPTION | Char | 30 | 8 | $30. | $30. | DX_METHOD_DESCRIPTION |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_NMCP_100_MILE_ZIPS | Observations: | 563 |
| Member Type: | DATA | Variables: | 5 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | CITY | Char | 50 | 8 | $50. | $50. | CITY |
| 5 | MILES_TO_SITE | Num | 8 | 80 | | | MILES_TO_SITE |
| 4 | POPULATION | Num | 8 | 72 | | | POPULATION |
| 3 | STATE | Char | 2 | 64 | $2. | $2. | STATE |
| 1 | ZIP_CODE | Char | 5 | 0 | $5. | $5. | ZIP_CODE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_NMCSD_100_MILE_ZIPS | Observations: | 566 |
| Member Type: | DATA | Variables: | 5 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | CITY | Char | 50 | 8 | $50. | $50. | CITY |
| 5 | MILES_TO_SITE | Num | 8 | 80 | | | MILES_TO_SITE |
| 4 | POPULATION | Num | 8 | 72 | | | POPULATION |
| 3 | STATE | Char | 2 | 64 | $2. | $2. | STATE |
| 1 | ZIP_CODE | Char | 5 | 0 | $5. | $5. | ZIP_CODE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_NNMC_100_MILE_ZIPS | Observations: | 1740 |
| Member Type: | DATA | Variables: | 5 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | CITY | Char | 50 | 8 | $50. | $50. | CITY |
| 5 | MILES_TO_SITE | Num | 8 | 80 | | | MILES_TO_SITE |
| 4 | POPULATION | Num | 8 | 72 | | | POPULATION |
| 3 | STATE | Char | 2 | 64 | $2. | $2. | STATE |
| 1 | ZIP_CODE | Char | 5 | 0 | $5. | $5. | ZIP_CODE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_WHMC_100_MILE_ZIPS | Observations: | 375 |
| Member Type: | DATA | Variables: | 5 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | CITY | Char | 50 | 8 | $50. | $50. | CITY |
| 5 | MILES_TO_SITE | Num | 8 | 80 | | | MILES_TO_SITE |
| 4 | POPULATION | Num | 8 | 72 | | | POPULATION |
| 3 | STATE | Char | 2 | 64 | $2. | $2. | STATE |
| 1 | ZIP_CODE | Char | 5 | 0 | $5. | $5. | ZIP_CODE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.STATIC_WRAMC_100_MILE_ZIPS | Observations: | 1749 |
| Member Type: | DATA | Variables: | 5 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 2 | CITY | Char | 50 | 8 | $50. | $50. | CITY |
| 5 | MILES_TO_SITE | Num | 8 | 80 | | | MILES_TO_SITE |
| 4 | POPULATION | Num | 8 | 72 | | | POPULATION |
| 3 | STATE | Char | 2 | 64 | $2. | $2. | STATE |
| 1 | ZIP_CODE | Char | 5 | 0 | $5. | $5. | ZIP_CODE |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.VIRAL_BURDEN | Observations: | 38805 |
| Member Type: | DATA | Variables: | 19 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 11 | APPROVED_DATE | Num | 8 | 128 | DATETIME20. | DATETIME20. | APPROVED_DATE |
| 10 | APPROVED_ID | Num | 8 | 120 | 7. | 7. | APPROVED_ID |
| 19 | BELOW_DETECTION | Num | 8 | 264 | | | BELOW_DETECTION |
| 13 | COMPONENT_ OCCURRENCE | Num | 8 | 144 | | | COMPONENT_ OCCURRENCE |
| 8 | DATE_COLLECTED | Num | 8 | 104 | DATETIME20. | DATETIME20. | DATE_COLLECTED |
| 7 | EVENT_OCCURRENCE | Num | 8 | 96 | | | EVENT_OCCURRENCE |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 9 | LABORATORY | Num | 8 | 112 | 5. | 5. | LABORATORY |
| 14 | LAB_CODE | Num | 8 | 152 | | | LAB_CODE |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 6 | PROTOCOL_SITE_CODE | Char | 30 | 64 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 12 | STATUS | Num | 8 | 136 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |
| 15 | VB_ASSAY | Num | 8 | 160 | | | VB_ASSAY |
| 16 | VB_ASSAY_T | Char | 50 | 168 | $50. | $50. | VB_ASSAY_T |
| 18 | VB_COPIES | Num | 8 | 256 | | | VB_COPIES |
| 17 | VB_QUALIFIER | Char | 30 | 224 | $30. | $30. | VB_QUALIFIER |

The SAS System

The CONTENTS Procedure

| | | | |
|---|---|---|---|
| Data Set Name: | NH.VISIT1 | Observations: | 33663 |
| Member Type: | DATA | Variables: | 11 |
| Engine: | ORACLE | Indexes: | 0 |
| Created: | . | Observation Length: | 0 |
| Last Modified: | . | Deleted Observations: | 0 |
| Protection: | | Compressed: | NO |
| Data Set Type: | | Sorted: | NO |
| Label: | | | |

-----Alphabetic List of Variables and Attributes-----

| # | Variable | Type | Len | Pos | Format | Informat | Label |
|---|---|---|---|---|---|---|---|
| 5 | ACTUAL_VISIT_DATE | Num | 8 | 56 | DATETIME20. | DATETIME20. | ACTUAL_VISIT_DATE |
| 10 | CLEANLINESS | Num | 8 | 120 | 5. | 5. | CLEANLINESS |
| 11 | DATE_ADDED | Num | 8 | 128 | DATETIME20. | DATETIME20. | DATE_ADDED |
| 3 | ID_DATA | Char | 30 | 16 | $30. | $30. | ID_DATA |
| 2 | PIN | Num | 8 | 8 | 7. | 7. | PIN |
| 8 | PROTOCOL_SITE_CODE | Char | 30 | 80 | $30. | $30. | PROTOCOL_SITE_CODE |
| 1 | RECIPE | Num | 8 | 0 | 5. | 5. | RECIPE |
| 7 | RSS_SITE_CODE | Num | 8 | 72 | 5. | 5. | RSS_SITE_CODE |
| 6 | SCHED_VISIT_DATE | Num | 8 | 64 | DATETIME20. | DATETIME20. | SCHED_VISIT_DATE |
| 9 | STATUS | Num | 8 | 112 | 5. | 5. | STATUS |
| 4 | STUDY_DAY | Num | 8 | 48 | 7. | 7. | STUDY_DAY |

# Data Dictionary for the Natural History Database

**Purpose**

The purpose of this document is to give an outline and understanding of the data structure of the Natural History Database. The data structure represents data elements that are captured on the Case Reporting Forms (CRFs). Familiarization with these forms will facilitate a better understanding of what data is being captured as well as where it is stored.

**Data Storage**

The Natural History data is stored in an Oracle® relational database. A relational database is built on the storage of data in tables that are related to each other. Each table in a relational database contains columns that help to define these relationships. Often columns are referred to as "fields".

Each week, data are converted, processed and exported out into this relational database. Thus, the data in the tables is updated weekly with new and corrected information. This is an important point when developing queries against this dataset.

**Table Types**

The Natural History database has several categories of data tables:

- general information tables
- code table;
- CRF-based tables
- "extra" data tables
- post-processed tables
- static tables

The first three groups of these tables are automatically generated as part of a dynamic process that takes information from the data entry module of RSS to a flat data structure. "Extra" data tables provide additional information from other data sources (for example, from other research protocols) as approved by the Principal Investigator. Post-processed tables are created by additional processing that is performed to facilitate easier querying and summarizing of data for research questions for the Natural History Study. A list of these tables can be found at the end of this document. Static tables are special tables of data used for a variety of reasons (for example, for grouping drugs into drug categories) and are updated only when needed.

**General Informational Tables**

There are two general informational tables: EXPORT_INFO and MASTER_ENROLLMENT.
EXPORT INFO has two rows. One row is for Protocol1 (Recipe = 0) while the other is for Protocol2 (Recipe = 1). To see the last export and conversion process times, query the columns EXPORT_STARTED and EXPORT_COMPLETED. The dates and times in these columns are refreshed each week as new data is loading into the Natural History database.

MASTER_ENROLLMENT will show the latest enrollment information, by PIN, in each protocol that is in the Research Support System (RSS). If a participant has transferred enrollment between sites, only the last enrollment is shown in this table. Protocol1 enrollments are NOT included in this table as of this time. An effort may be made in the future to load that information into this table. Information about Protocol1 enrollments can be derived from the ENROLLMENT CRF-based table as described below.

**Code Tables**

Since data are stored in a relational database, codes are often used to increase s storage capacity, enforce integrity of data and provide a concise way of viewing data. However, many times codes can be arbitrary or cryptic to those who are not familiar with the dataset. A series of automated code tables will be produced each time the data is exported from the RSS application. This will provide the most recently included or modified code listings.

All of the code tables that are automatically created begin with the prefix: "PROTOCOL_". Below is a listing of code tables:

| | |
|---|---|
| PROTOCOL_CLEANLINESS | This table gives the meaning to the cleanliness column in the CRF-based tables. Mostly, it can be ignored. It is used to track the quality of the data and used internally. |
| PROTOCOL_LABORATORY | This is a code table for applicable laboratories. This table can be ignored since it only contains the code (-2) for 'N/A'. Laboratories have been recorded using a different field in this study. |
| PROTOCOL_LOOKUP_CODES | This is one of the most useful codes tables. It contains each coded column and its meaning. Using the EVENT_NAME (Table) and COMPONENT_NAME (Column), several descriptions are provided. Use this table to help format reports and translate codes. |
| PROTOCOL_PERSON | This code table contains specific links to determine the Research Coordinator/Investigator who submitted a CRF. Join the PERSON_ID field to the APPROVED_BY field any of the CRF based tables to find the full name of the person. |

| | |
|---|---|
| PROTOCOL_SITE | This code table makes several links between the field PROTOCOL_SITE_CODE and its descriptions. Join the PROTOCOL_SITE_CODE field to this table to find the Formal Site Name for reporting. Protocol Site Codes are alphanumeric, so you must use the full 2 digit code, for example, '01' instead of '1'. |
| PROTOCOL_STATUS | This table gives the meaning to the status column in the CRF-based tables. Mostly, it can be ignored. It is used to track whether the required data was supplied. |
| PROTOCOL_USER | This is actually not a true code table. However, it reflects all the people who have access to the dataset. |

**CRF-based Tables**

There are twenty-two CRF-based tables that available in the Natural History Database. In addition there is a table called VISIT1. This table contains research visit information for each participant. With these twenty-three tables, it is easy to perform quality assurance in matching the data with CRFs used in Protocol2.

The CRF-based tables have a common structure. The first thirteen columns of each of these tables (excluding VISIT1) are called "Standard Header Columns". The remaining columns, called "Component Columns" reflect the individual fields on the CRF. Many of the Standard Header Columns are not used or applicable in the Natural History Protocol. In other protocols, these columns have specific meanings. An explanation of the standard header columns follows.




**Standard Header Columns Information**

| | |
|---|---|
| RECIPE | This corresponds to the recipe that is found within a protocol and phase. It is a way to stratify the database. In our case, Protocol1 will be Recipe 0 and Protocol2 will be Recipe 1. |
| PIN | This is the unique identifier for each participant. |
| ID_DATA | This is an alternate identifier for each participant. |
| STUDY_DAY | This is the sequential time element to the protocols. It indicates the day of the participant's visit. For Protocol1, since there was no true visit number, this field is calculated based on the participant's Miscellaneous Exam visit. For Protocol2 data, this corresponds with the actual visit number that is in the header of the CRF. |
| ACTUAL_VISIT_DATE | This is the date on which the study visit took place. This corresponds with the actual visit date that is in the header of the CRF. |
| PROTOCOL_SITE_CODE | This is the code that is used for the site where the visit occurred. Note that it is an alphanumeric character, so if there is a leading |

| | |
|---|---|
| | zero, the zero cannot be dropped or ignored. The translation for this code can be found in a table called PROTOCOL_SITE. |
| EVENT_OCCURRENCE | This represents the occurrence number of the event during a visit. For example, if there are three sets of viral burden results recorded on the same visit, there will be three event occurrences numbered one to three in the database for the participant on this particular STUDY_DAY (Visit Number). For most uses, this column can be ignored. |
| DATE_COLLECTED | This represents the date that all the components of this table were recorded, captured or tested as defined on the CRFs. This is an important column for joining data between tables. |
| LABORATORY | This represents the physical laboratory where the results were obtained. In most cases, this field is unused; rather a component column called "Lab Code" is set aside to define the physical laboratory location. |
| APPROVED_ID | This represents the person who signed, authorized or reviewed the data on this event. This is a numerically coded column. The codes can be found in the table called PROTOCOL_PERSON. |
| APPROVED_DATE | This represents the data on which the data of this event was signed, authorized, or reviewed. |
| STATUS | This represents the status of the event as a whole. These statuses are codes that are defined for each protocol. The codes for these statuses can be found in a table called PROTOCOL_STATUS. For most uses, this column can be ignored. |
| COMPONENT_OCCURRENCE | This represents the occurrence of each of the components below during this event. It can be thought of as the line numbers of a particular event. For most uses, this column can be ignored. |

Component Columns vary from table to table. However, there are some general rules that apply to these columns.

_T Columns that end in '_T' represent associated text with the base component. This normally reflects comments or fields that require information on the CRF to be specified as a short text.

Example:

In the figure of the Viral Burden table there are two component columns VB_ASSAY and VB_ASSAY_T. They differ only by the "_T". In this case, VB_ASSAY is the coded viral burden assay type. However, if code 99 ("Other") is entered, the name of the viral burden assay type will be stored in the VB_ASSAY_T column.

| | |
|---|---|
| _S | Columns that end in '_S' represent the status of the base component. To date, no individual component statuses have been set to export, so this should not be seen in any CRF-based tables in the Natural History Database. |

**Extra Tables**

These tables are derived from their original source. At present, the only table in this category is EXTRA_CERT_VB. This table provides all CERT viral burdens for participants enrolled in both protocols, excluding those collected in the preceding two weeks, which is the CERT blackout period. These CERT viral burdens may have also been reported in the Natural History Lymphocyte Profile table, because the research coordinators have been instructed to report the CERT viral burdens on the Lymphocyte Profile case report form.

**Post-processed Tables**

Derived from the CRF-based tables, the post-processed tables may have the most usage when developing complex queries. These types of tables are used to summarize, group and join the data together in a way to more easily facilitate research and reporting. Many of the pre-built Standardized Natural History Queries are in fact built off some of these underlying tables. The tables hide the complexity of some advance querying techniques by providing the data in a pre-assembled format.

All the tables in this category are prefixed by the "POST_" name. This makes it easy to distinguish the tables from the actual data submitted via the CRF (in the CRF-based tables).

The following list of post-processed tables may not be complete, as additional tables are designed and implemented.

| | |
|---|---|
| POST_ALL_AF_STAGE | This tables combines the Armed Forces staging data from the STAGING_HISTORY and MISC_EXAM CRF tables. |
| POST_ALL_BLOOD_CHEM_IMM | This data combines the data from the BLOOD_CHEMISTRY and CHEMISTRY_IMMUNOLOGY CRF tables. |
| POST_BIO_CHILDREN | This table contains the dates of birth of biological children as given in the DEMOGRAPHY table. This table can be used with the POST_CURRENT_DEMOGRAPHY table to get complete demographic information. If the participant has no biological children, there will be no rows for that PIN. |
| POST_CLINICAL_RESULTS | This table combines viral burden, CD4 counts and Armed Forces staging data from three tables. Not every row will have data for all three measures, since viral burdens, CD4 counts and staging assessments may have been done on different dates. |

| | |
|---|---|
| POST_CURRENT_DEMOGRAPHY | This table gives the most recently reported information for each variable on the DEMOGRAPHY CRF. This means that variables might come from several different study days (visits). There is 1 row per participant. The PROTOCOL_SITE_CODE and STUDY_DAY information comes from the most recently reported DEMOGRAPHY information, which may not be the most recent visit. |
| POST_DEMOGRAPHY | In this table, variables are "filled in" from previous values if they are missing. Recall that the DEMOGRAPHY CRF is filled out only for those variables which are different since the last report. Thus, for example, marital status might be reported on the initial CRF, and subsequently only if it changes. Looking at CRFs from dates between these two would show marital status as missing. In the POST_DEMOGRAPHY table, the initial marital status will be shown for all the CRFs from the initial one until it changes, or if it never does, until the most recent CRF. |
| POST_DIAGNOSIS_CODE | This table provides a method of categorizing diagnoses by diagnoses type and the recipe under which they were collected. |
| POST_DRUG_CODE | This table provides a method of categorizing drugs by drug type and the recipe under which they were collected. |
| POST_DRUG_REGIMEN | In this table, distinct episodes of combinations of antiviral drugs are summarized with a start date and a stop date. Each row summarizes the distinct combination of selected antiviral drugs that occurred during a single time period, and is marked by a sequential "regimen number". If a participant has never been on antiviral therapy, there is only 1 row for that PIN, with REGIMEN_NUMBER=0. The individual drugs that are summarized in this table are also shown as variables that take on the value 'Y' or 'N' to show whether the participant was on that drug during that regimen number. There are also three summary variables: ON_PI_YN, ON_NRTI_YN, and ON_NNRTI_YN. A null stop date means the regimen is ongoing as of the last reported research visit. |
| POST_MEDICAL_HISTORY | The table has the columns LOCUS and METHOD updated with the method and locus values sorted alphanumerically. In addition, the column DX_CODE_T contains a description of the diagnosis either from the definition of the code or, in the case of "Other Specify" diagnoses, the comments provided. |
| POST_MEDICAL_HIST_SUMMARY | This table "collapses" information about a diagnosis episode from more than one row in the MEDICAL_HISTORY table into a single row with a start date and an end date. Multiple reports of a diagnosis with the same start date are combined into one row to provide a unique start and end date. In some cases there may be more than 1 row if there are different locus or method codes. |

| | |
|---|---|
| POST_MEDICATION | This table has medication data with the column DRUG_CODE_T populated with the medication name, when it is not already provided on the CRF. |
| POST_MEDICATION_SUMMARY | This table "collapses" information about a medication episode from more than one row in the MEDICATION table into a single row. Multiple reports of a medication with the same start date are combined into one row to provide a unique start and stop date. In some cases there may be more than 1 row if there are different indication codes or routes. |
| POST_SKIN_TEST_SUMMARY | This table summarizes distinct periods of normal, partial and complete skin test reactivity with a start date and an end date. Each row summarizes a period when reactivity was consistent, and is marked by a sequential "skin test number" for purposes of distinguishing and ordering the periods. |

The list below gives an itemization of tables within each category of tables.

CRF-based Tables
BLOOD_CHEMISTRY
CHEMISTRY_IMMUNOLOGY
DEATH_SUMMARY
DEMOGRAPHY
DEXASCAN
DRUG_ALLERGY
ENROLLMENT
HEMATOLOGY
HIV_SUBTYPE
HOSPITALIZATION
IMMUNIZATION
LYMPHOCYTE_PROFILE
MEDICAL_HISTORY
MEDICATION
MISC_EXAM
MISC_FINDINGS
NONB_SCREENING
QUALITY_OF_LIFE
RECLASSIFICATION
SEROLOGY
STAGING_HISTORY
VIRAL_BURDEN
VISIT1

Code Tables
PROTOCOL_CLEANLINESS
PROTOCOL_LABORATORY
PROTOCOL_LOOKUP_CODES
PROTOCOL_PERSON
PROTOCOL_SITE
PROTOCOL_STATUS
PROTOCOL_USER

Post-Processed Tables
POST_ALL_AF_STAGE
POST_ALL_BLOOD_CHEM_IMM
POST_BIO_CHILDREN
POST_CLINICAL_RESULTS
POST_CURRENT_DEMOGRAPHY
POST_DEMOGRAPHY
POST_DIAGNOSIS_CODE
POST_DRUG_CODE
POST_DRUG_REGIMEN
POST_MEDICAL_HISTORY
POST_MEDICAL_HIST_SUMMARY
POST_MEDICATION
POST_MEDICATION_SUMMARY
POST_SKIN_TEST_SUMMARY

General Information Tables
EXPORT_INFO
MASTER_ENROLLMENT

Extra Data Tables
EXTRA_CERT_VB

Static Tables of Interest

| | |
|---|---|
| STATIC_ 100_MILE_ZIPS | These tables give a list of ZIP codes within 100 miles of a given clinical site and their actual distance to the center of the ZIP code where the clinical site is located. This data was downloaded from the Internet. |
| STATIC_SPECIMEN_CRF | Matches submitted for specimens. This table forms the basis for the Outstanding CRFs report. |
| STATIC_DRUG_SCORE | Based on the POST_DRUG_REGIMEN table. It also includes lifetime cumulative days on a particular drug or class of drugs as of the start of this drug regimen. This attempts to measure intensity of treatment. For example, the column SCORE_AZT gives the lifetime number of days on AZT for this particpant as of the start of the current drug regimen. Similarly, the SCORE_PI gives the combined lifetime days on protease inhibitors at the start of this |

| | |
|---|---|
| | drug regimen. For example, 10 days on Indinavir prior to the beginning of this regimen, plus 30 days on Nelfinavir prior to the beginning of this regimen, would give a SCORE_PI=40 for this regimen. By definition, all scores=0 for regimen 1 and regimen 0. |
| STATIC_DRUG_SYNONYM | This table contains a list of drug codes used and various synonyms such as generic or trade names corresponding to these codes. |

**TACC PUBLICATIONS:**


1. Redfield R, Markham P, Salahuddin S, Sarngadharan M, Bodner A, Folks T, et al. Frequent transmission of HTLV-III among spouses of patients with AIDS-related complex and AIDS. JAMA 1985; 253(11): p1571-3.
2. Burke D, Redfield R. Classification of infections with human immunodeficiency virus. Ann Intern Med 1986;105(6): p968.
3. Cohen I, Anderson D, Virmani R, Reen B, Macher A, Sennesh J, et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 1986;315(10): p628-30.
4. Redfield R, Wright D, Tramont E. The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med 1986;314(2): p131-2.
5. Sumaya C, Boswell R, Ench Y, Kisner D, Hersh E, Reuben J, et al. Enhanced serological and virological findings of Epstein-Barr virus in patients with AIDS and AIDS-related complex. J Infect Dis 1986;154(5): p864-70.
6. Whitney E, Boswell R. Cardiovascular risk modification: a multidisciplinary approach in a USAF clinic setting. Mil Med 1986;151(9): p473-7.
7. Burke D, Brundage J, Herbold J, Berner W, Gardner L, Gunzenhauser J, et al. Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. Demographic factors associated with seropositivity. N Engl J Med 1987;317(3): p131-6.
8. Burke D, Brundage J, Bernier W, Gardner L, Redfield R, Gunzenhauser J, et al. Demography of HIV infections among civilian applicants for military service in four counties in New York City. N Y State J Med 1987;87(5): p262-4.
9. Burke D, Brandt B, Redfield R, Lee T, Thorn R, Beltz G, et al. Diagnosis of human immunodeficiency virus infection by immunoassay using a molecularly cloned and expressed virus envelope polypeptide. Comparison to Western blot on 2707 consecutive serum samples. Ann Intern Med 1987;106(5): p671-6.
10. Kennedy R, Dreesman G, Chanh T, Boswell R, Allan J, Lee T, et al. Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope. J Biol Chem 1987;262(12): p5769-74.
11. Lennox J, Redfield R, Burke D. HIV antibody screening in a general hospital population. JAMA 1987;257(21): p2914.
12. Lupton G, James W, Redfield R, Brown C, Rodman O. Oral hairy leukoplakia. A distinctive marker of human T-cell lymphotropic virus type III (HTLV-III) infection. Arch Dermatol 1987;123(5): p624-8.
13. Redfield R, Wright D, James W, Jones T, Brown C, Burke D. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987;316(11): p673-6.
14. Tramont E. Syphilis in the AIDS era. N Engl J Med 1987;316(25): p1600-1.
15. Alsip G, Ench Y, Sumaya C, Boswell R. Increased Epstein-Barr virus DNA in oropharyngeal secretions from patients with AIDS, AIDS-related complex, or asymptomatic human immunodeficiency virus infections. J Infect Dis 1988;157(5): p1072-6.
16. Appleman M, Marshall D, Brey R, Houk R, Beatty D, Winn R, et al. Cerebrospinal fluid abnormalities in patients without AIDS who are seropositive for the human immunodeficiency virus. J Infect Dis 1988;158(1): p193-9.
17. Berger R, Stoner M, Hobbs E, Hayes T, Boswell R. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol 1988;19(2 Pt 1): p298-303.

18. Boswell R. AIDS in Arkansas. AIDS 1988. J Ark Med Soc 1988;85(2): p73-85.
19. Brundage J, Burke D, Gardner L, Visintine R, Peterson M, Redfield R. HIV infection among young adults in the New York City area. Prevalence and incidence estimates based on antibody screening among civilian applicants for military service. N Y State J Med 1988;88(5): p232-5.
20. Burke D, Brundage J, Redfield R, Damato J, Schable C, Putman P, et al. Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N Engl J Med 1988;319(15): p961-4.
21. Fling J, Fischer J, Boswell R, Reid M. The relationship of serum IgA concentration to human immunodeficiency virus (HIV) infection: a cross-sectional study of HIV-seropositive individuals detected by screening in the United States Air Force. J Allergy Clin Immunol 1988;82(6): p965-70.
22. Grieger T, Carl M, Liebert H, Cotelingam J, Wagner K. Mediastinal liposarcoma in a patient infected with the human immunodeficiency virus. Am J Med 1988;84(2): p366.
23. Marshall D, Brey R, Cahill W, Houk R, Zajac R, Boswell R. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 1988;45(9): p954-8.
24. Reid M, Goetz D, Zajac R, Houk R, Boswell R. The natural history of human immunodeficiency virus infection in screened HIV positive U.S. Air Force personnel: a preliminary report. J Acquir Immune Defic Syndr 1988;1(5): p508-15.
25. Rundell J, Paolucci S, Beatty D, Boswell R. Psychiatric illness at all stages of human immunodeficiency virus infection. Am J Psychiatry 1988;145(5): p652-3.
26. Bjornson D, Meyer D, Hiner W, Tramont E. Prescription drug use patterns of human immunodeficiency virus-infected patients taking zidovudine. Walter Reed Retrovirus Research Group. DICP 1989;23(9): p698-702.
27. Burke D, Redfield R, Bjornson D, Fowler A, Oster C. Frequent isolation of HIV-1 from the blood of patients receiving zidovudine (AZT) therapy. N Engl J Med 1989;321(24): p1682.
28. Clerici M, Stocks N, Zajac R, Boswell R, Lucey D, Via C, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989;84(6): p1892-9.
29. Clerici M, Stocks N, Zajac R, Boswell R, Bernstein D, Mann D, et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989;339(6223): p383-5.
30. Dannenberg A, McNeil J, Brundage J. Mortality among 1862 HIV-antibody-positive civilian applicants for military service: preliminary results. N Engl J Med 1989;321(18): p1267-8.
31. Di CF, Anderson D, Virmani R, Burns W, Macher A, Rotiguez J, et al. Rheumatic heart disease in a patient with acquired immunodeficiency syndrome. Hum Pathol 1989;20(9): p917-20.
32. Gardner L, Brundage J, Burke D, McNeil J, Visintine R, Miller R. Evidence for spread of the human immunodeficiency virus epidemic into low prevalence areas of the United States. J Acquir Immune Defic Syndr 1989;2(6): p521-32.
33. Garland F, Mayers D, Hickey T, Miller M, Shaw E, Gorham E, et al. Incidence of human immunodeficiency virus seroconversion in US Navy and Marine Corps personnel, 1986 through 1988. JAMA 1989;262(22): p3161-5.
34. Goethe K, Mitchell J, Marshall D, Brey R, Cahill W, Leger G, et al. Neuropsychological and neurological function of human immunodeficiency virus seropositive asymptomatic individuals. Arch Neurol 1989;46(2): p129-33.

35. Golding H, Shearer G, Hillman K, Lucas P, Manischewitz J, Zajac R, et al. Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest 1989;83(4): p1430-5.
36. Kornhauser D, Petty B, Hendrix C, Woods A, Nerhood L, Bartlett J, et al. Probenecid and zidovudine metabolism. Lancet 1989;2(8661): p473-5.
37. McNeil J, Brundage J, Wann Z, Burke D, Miller R. Direct measurement of human immunodeficiency virus seroconversions in a serially tested population of young adults in the United States Army, October 1985 to October 1987. Walter Reed Retrovirus Research Group. N Engl J Med 1989;320(24): p1581-5.
38. Melcher G. AIDS in Arkansas. The immunopathogenesis of human immunodeficiency virus. J Ark Med Soc 1989;85(11): p479-83.
39. Redfield R, Tramont E. Toward a better classification system for HIV infection. N Engl J Med 1989;320(21): p1414-6.
40. Ridley D, Houk R, Reid M, Boswell R. Early lymphocyte transformation abnormalities in human immunodeficiency virus infection. J Clin Immunol 1989;9(2): p119-24.
41. Anderson D, Virmani R. Emerging patterns of heart disease in human immunodeficiency virus infection. Hum Pathol 1990;21(3): p253-9.
42. Brundage J, Burke D, Gardner L, McNeil J, Goldenbaum M, Visintine R, et al. Tracking the spread of the HIV infection epidemic among young adults in the United States: results of the first four years of screening among civilian applicants for U.S. military service. J Acquir Immune Defic Syndr 1990;3(12): p1168-80.
43. Brundage J, McNeil J, Miller R, Gardner L, Harrison S, Hawkes C, et al. The current distribution of CD4+ T-lymphocyte counts among adults in the United States with human immunodeficiency virus infections: estimates based on the experience of the U.S. Army. U.S. Army Retrovirus Research Group. J Acquir Immune Defic Syndr 1990;3(1): p92-4.
44. Burke D, Brundage J, Goldenbaum M, Gardner L, Peterson M, Visintine R, et al. Human immunodeficiency virus infections in teenagers. Seroprevalence among applicants for US military service. The Walter Reed Retrovirus Research Group. JAMA 1990;263(15): p2074-7.
45. Burke D, Fowler A, Redfield R, Dilworth S, Oster C. Isolation of HIV-1 from the blood of seropositive adults: patient stage of illness and sample inoculum size are major determinants of a positive culture. The Walter Reed Retroviral Research Group. J Acquir Immune Defic Syndr 1990;3(12): p1159-67.
46. Clerici M, Stocks N, Zajac R, Boswell R, Via C, Shearer G. Circumvention of defective CD4 T helper cell function in HIV-infected individuals by stimulation with HLA alloantigens. J Immunol 1990;144(9): p3266-71.
47. Clerici M, Stocks N, Zajac R, Boswell R, Shearer G. Accessory cell function in asymptomatic human immunodeficiency virus-infected patients. Clin Immunol Immunopathol 1990;54(2): p168-73.
48. Cowan D, Pomerantz R, Wann Z, Goldenbaum M, Brundage J, Miller R, et al. Human immunodeficiency virus infection among members of the reserve components of the US Army: prevalence, incidence, and demographic characteristics. The Walter Reed Retrovirus Research Group. J Infect Dis 1990;162(4): p827-36.
49. Drabick J, Tramont E. Utility of the VDRL test in HIV-seropositive patients. N Engl J Med 1990;322(4): p271.
50. Fuchs D, Shearer G, Boswell R, Clerici M, Reibnegger G, Werner E, et al. Increased serum neopterin in patients with HIV-1 infection is correlated with reduced in vitro interleukin-2 production. Clin Exp Immunol 1990;80(1): p44-8.

51. Gomatos P, Stamatos N, Gendelman H, Fowler A, Hoover D, Kalter D, et al. Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and T cells. J Immunol 1990;144(11): p4183-8.
52. Kelley P, Miller R, Pomerantz R, Wann F, Brundage J, Burke D. Human immunodeficiency virus seropositivity among members of the active duty US Army 1985-89. Am J Public Health 1990;80(4): p405-10.
53. Lucey D, Zajac R, Melcher G, Butzin C, Boswell R. Serum IgE levels in 622 persons with human immunodeficiency virus infection: IgE elevation with marked depletion of CD4+ T-cells. AIDS Res Hum Retroviruses 1990;6(4): p427-9.
54. Lucey D, Hendrix C, Andrzejewski C, McGlasson D, Ward W, Melcher G, et al. Hepatitis C antibody in a non-hemophiliac U.S. Military HIV infected population infected with the human immunodeficiency virus. Viral Immunol 1990;3(4): p295-301.
55. Lucey D, Milum S, Lindquist C, Andrzejewski C, Benton J, Boswell R. Pseudofailure of zidovudine prophylaxis after a human immunodeficiency virus-positive needlestick. J Infect Dis 1990;162(5): p1211-2.
56. Renzullo P, McNeil J, Levin L, Bunin J, Brundage J. Risk factors for prevalent human immunodeficiency virus (HIV) infection in active duty Army men who initially report no identified risk: a case-control study. J Acquir Immune Defic Syndr 1990;3(3): p266-71.
57. Warren R, Wolf H, Shuler K, Eichberg J, Zajac R, Boswell R, et al. Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees. J Virol 1990;64(2): p486-92.
58. Birx D, Rhoads J, Wright J, Burke D, Redfield R. Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness. J Acquir Immune Defic Syndr 1991;4(2): p188-96.
59. Bjornson D, Oster C, Hiner W, Tramont E. The relationship between outpatient drug costs and disease progression in the human immunodeficiency virus-infected population. The Military Medical Consortium for Applied Retroviral Research. DICP 1991;25(4): p414-7.
60. Blatt S, Lucey D, De HD, Zellmer R. Rhinocerebral zygomycosis in a patient with AIDS. J Infect Dis 1991;164(1): p215-6.
61. Brey R, Arroyo R, Boswell R. Cerebrospinal fluid anti-cardiolipin antibodies in patients with HIV-1 infection. J Acquir Immune Defic Syndr 1991;4(4): p435-41.
62. Clerici M, Tacket C, Via C, Lucey D, Muluk S, Zajac R, et al. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur J Immunol 1991;21(6): p1345-9.
63. Clerici M, Lucey D, Zajac R, Boswell R, Gebel H, Takahashi H, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol 1991;146(7): p2214-9.
64. Clerici M, Landay A, Kessler H, Zajac R, Boswell R, Muluk S, et al. Multiple patterns of alloantigen presenting/stimulating cell dysfunction in patients with AIDS. J Immunol 1991;146(7): p2207-13.
65. Cowan D, Brundage J, Pomerantz R, Miller R, Burke D. HIV infection among members of the US Army Reserve Components with medical and health occupations. JAMA 1991;265(21): p2826-30.
66. De GA, Clerici M, Hosmalin A, Hughes S, Barnd D, Hendrix C, et al. Human immunodeficiency virus reverse transcriptase T helper epitopes identified in mice and humans: correlation with a cytotoxic T cell epitope. J Infect Dis 1991;164(6): p1058-65.
67. Drabick J, Horning V, Lennox J, Coyne P, Oster C, Knight R, et al. A retrospective analysis of diseases associated with indeterminate HIV western blot patterns. Mil Med 1991;156(2): p93-6.

68. Flexner C, Barditch-Crovo P, Kornhauser D, Farzadegan H, Nerhood L, Chaisson R, et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob Agents Chemother 1991;35(12): p2544-50.
69. Fuchs D, Shearer G, Boswell R, Lucey D, Clerici M, Reibnegger G, et al. Negative correlation between blood cell counts and serum neopterin concentration in patients with HIV-1 infection. AIDS 1991;5(2): p209-12.
70. Hendrix C, Volberding P, Chaisson R. HIV antigen variability in ARC/AIDS. J Acquir Immune Defic Syndr 1991;4(9): p847-50.
71. La RG, Weinhold K, Profy A, Langlois A, Dreesman G, Boswell R, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications. Science 1991;253(5024): p1146.
72. Longini I, Clark W, Gardner L, Brundage J. The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach. J Acquir Immune Defic Syndr 1991;4(11): p1141-7.
73. Lucey D, Melcher G, Hendrix C, Zajac R, Goetz D, Butzin C, et al. Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell counts. J Infect Dis 1991;164(4): p631-7.
74. Lucey D, McGuire S, Clerici M, Hall K, Benton J, Butzin C, et al. Comparison of spinal fluid beta 2-microglobulin levels with CD4+ T cell count, in vitro T helper cell function, and spinal fluid IgG parameters in 163 neurologically normal adults infected with the human immunodeficiency virus type 1. J Infect Dis 1991;163(5): p971-5.
75. Lucey D, Nunley M, Boswell R, Koopman T, Hensley R, Ward W. HLA-DR+ CD8+ T cells in the cerebrospinal fluid of a patient with AIDS dementia complex and 355-494/mm3 CD4+ peripheral blood T cells. J Acquir Immune Defic Syndr 1991;4(6): p638-9.
76. Lucey D, Hensley R, Ward W, Butzin C, Boswell R. CD4+ monocyte counts in persons with HIV-1 infection: an early increase is followed by a progressive decline. J Acquir Immune Defic Syndr 1991;4(1): p24-30.
77. Marshall D, Brey R, Butzin C, Lucey D, Abbadessa S, Boswell R. CSF changes in a longitudinal study of 124 neurologically normal HIV-1-infected U.S. Air Force personnel. J Acquir Immune Defic Syndr 1991;4(8): p777-81.
78. McNeil J, Brundage J, Gardner L, Wann Z, Renzullo P, Redfield R, et al. Trends of HIV seroconversion among young adults in the US Army, 1985 to 1989. US Army Retrovirus Research Group. JAMA 1991;265(13): p1709-14.
79. Redfield R, Birx D, Ketter N, Tramont E, Polonis V, Davis C, et al. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med 1991;324(24): p1677-84.
80. Renzullo P, McNeil J, Gardner L, Brundage J. Inpatient morbidity among HIV-infected male soldiers prior to their diagnosis of HIV infection. Am J Public Health 1991;81(10): p1280-4.
81. Rhoads J, Birx D, Wright D, Brundage J, Brandt B, Redfield R, et al. Safety and immunogenicity of multiple conventional immunizations administered during early HIV infection. J Acquir Immune Defic Syndr 1991;4(7): p724-31.
82. Tramont E. Controversies regarding the natural history and treatment of syphilis in HIV disease. Paper presented at: AIDS Clin Rev, 1991.
83. Wages J, Hamdallah M, Calabro M, Fowler A, Oster C, Redfield R, et al. Clinical performance of a polymerase chain reaction testing algorithm for diagnosis of HIV-1 infection in peripheral blood mononuclear cells. J Med Virol 1991;33(1): p58-63.

84. Warren R, Wolf H, Zajac R, Boswell R, Kanda P, Kennedy R. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels. J Clin Immunol 1991;11(1): p13-21.
85. Clerici M, Landay A, Kessler H, Phair J, Venzon D, Hendrix C, et al. Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. J Infect Dis 1992;166(4): p723-30.
86. Drabick J, Williams W, Tang D, Sun W, Chung R. CD4 lymphocyte decline and survival in human immunodeficiency virus infection. The Military Medical Consortium for Applied Retroviral Research. AIDS Res Hum Retroviruses 1992;8(12): p2039-47.
87. Gardner L, Brundage J, McNeil J, Milazzo M, Redfield R, Aronson N, et al. Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army Natural History Cohort. Military Medical Consortium for Applied Retrovirology. J Acquir Immune Defic Syndr 1992;5(8): p782-93.
88. Lucey D, Hendrix C, Andrzejewski C, Melcher G, Butzin C, Henry R, et al. Comparison by race of total serum IgG, IgA, and IgM with CD4+ T-cell counts in North American persons infected with the human immunodeficiency virus type 1. J Acquir Immune Defic Syndr 1992;5(4): p325-32.
89. Malone J, Oldfield E, Wagner K, Simms T, Daly R, O'Brian J, et al. Abnormalities of morning serum cortisol levels and circadian rhythms of CD4+ lymphocyte counts in human immunodeficiency virus type 1-infected adult patients. J Infect Dis 1992;165(1): p185-6.
90. Mayers D, McCutchan F, Sanders-Buell E, Merritt L, Dilworth S, Fowler A, et al. Characterization of HIV isolates arising after prolonged zidovudine therapy. J Acquir Immune Defic Syndr 1992;5(8): p749-59.
91. Michael N, Vahey M, Burke D, Redfield R. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J Virol 1992;66(1): p310-6.
92. Nkya W, Warren R, Wolf H, Hendrix C, Tesha J, Redfield R, et al. Fine specificity of the humoral immune response to HIV-1 GP160 in HIV-1 infected individuals from Tanzania. J Med Virol 1992;37(1): p61-6.
93. Redfield R, Birx D, Ketter N, Polonis V, Johnson S, Davis C, et al. Vaccine therapy using rgp 160 in early HIV infection. AIDS Res Hum Retroviruses 1992;8(8): p1333.
94. Robb M, Polonis V, Vahey M, Gartner S, Michael N, Fowler A, et al. HIV neutralization assay using polymerase chain reaction-derived molecular signals. J Acquir Immune Defic Syndr 1992;5(12): p1224-9.
95. Roberts C, Fipps D, Brundage J, Wright S, Goldenbaum M, Alexander S, et al. Prevalence of human T-lymphotropic virus in civilian applicants for the United States Armed Forces. Am J Public Health 1992;82(1): p70-3.
96. Smith K, Konzelman J, Lombardo F, Skelton H, Holland T, Yeager J, et al. Iontophoresis of vinblastine into normal skin and for treatment of Kaposi's sarcoma in human immunodeficiency virus-positive patients. The Military Medical Consortium for Applied Retroviral Research. Arch Dermatol 1992;128(10): p1365-70.
97. Smith K, Skelton H, Yeager J, James W, Wagner K. Molluscum contagiosum. Ultrastructural evidence for its presence in skin adjacent to clinical lesions in patients infected with human immunodeficiency virus type 1. Military Medical Consortium for Applied Retroviral Research. Arch Dermatol 1992;128(2): p223-7.

98. Warren R, Anderson S, Nkya W, Shao J, Hendrix C, Melcher G, et al. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity. J Virol 1992;66(9): p5210-5.
99. Warren R, Nkya W, Shao J, Anderson S, Wolf H, Hendrix C, et al. Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States. J Clin Microbiol 1992;30(1): p126-31.
100. Weiss P, Brodine S, Goforth R, Kennedy C, Wallace M, Olson P, et al. Initial low CD4 lymphocyte counts in recent human immunodeficiency virus infection and lack of association with identified coinfections. J Infect Dis 1992;166(5): p1149-53.
101. Birx D, Brundage J, Larson K, Engler R, Smith L, Squire E, et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr 1993;6(11): p1248-57.
102. Blatt S, Hendrix C, Butzin C, Freeman T, Ward W, Hensley R, et al. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 1993;119(3): p177-84.
103. Blatt S, Lucey C, Butzin C, Hendrix C, Lucey D. Total lymphocyte count as a predictor of absolute CD4+ count and CD4+ percentage in HIV-infected persons. JAMA 1993;269(5): p622-6.
104. Clerici M, Lucey D, Berzofsky J, Pinto L, Wynn T, Blatt S, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262(5140): p1721-4.
105. Clerici M, Yarchoan R, Blatt S, Hendrix C, Ammann A, Broder S, et al. Effect of a recombinant CD4-IgG on in vitro T helper cell function: data from a phase I/II study of patients with AIDS. J Infect Dis 1993;168(4): p1012-6.
106. Clerici M, Hakim F, Venzon D, Blatt S, Hendrix C, Wynn T, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993;91(3): p759-65.
107. Cowan D, Brundage J, Pomerantz R, Wann Z, Miller R. Risk of HIV infection among Army Reserve Components physicians. Am J Public Health 1993;83(11): p1640-1.
108. Dolan M, Lucey D, Hendrix C, Melcher G, Spencer G, Boswell R. Early markers of HIV infection and subclinical disease progression. Vaccine 1993;11(5): p548-51.
109. Erice A, Mayers D, Strike D, Sannerud K, McCutchan F, Henry K, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993;328(16): p1163-5.
110. Gorham E, Garland F, Mayers D, Goforth R, Brodine S, Wiess P, et al. CD4 lymphocyte counts within 24 months of human immunodeficiency virus seroconversion. Findings in the US Navy and Marine Corps. The Navy Retroviral Working Group. Arch Intern Med 1993;153(7): p869-76.
111. Japour A, Mayers D, Johnson V, Kuritzkes D, Beckett L, Arduino J, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother 1993;37(5): p1095-101.

112. Kennedy C, Pimentel J, Lewis D, Anderson M, Weiss P, Oldfield E. Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: lack of hematologic toxicity and relationship of side effects to CD4+ lymphocyte count. J Infect Dis 1993;168(2): p314-7.
113. Lucey D, McCarthy W, Blatt S, Melcher G, Hendrix C. Racial differences in serum beta 2-microglobulin in persons with human immunodeficiency virus infection. J Infect Dis 1993;167(5): p1259-60.
114. Lucey D, Van CT, Loomis L, Bethke F, Hendrix C, Melcher G, et al. Measurement of cerebrospinal fluid antibody to the HIV-1 principal neutralizing determinant (V3 loop). J Acquir Immune Defic Syndr 1993;6(9): p994-1001.
115. Lucey D, McGuire S, Abbadessa S, Hall K, Woolford B, Valtier S, et al. Cerebrospinal fluid neopterin levels in 159 neurologically asymptomatic persons infected with the human immunodeficiency virus (HIV-1): relationship to immune status. Viral Immunol 1993;6(4): p267-72.
116. Michael N, Chang G, Ehrenberg P, Vahey M, Redfield R. HIV-1 proviral genotypes from the peripheral blood mononuclear cells of an infected patient are differentially represented in expressed sequences. J Acquir Immune Defic Syndr 1993;6(10): p1073-85.
117. Schulick R, Clerici M, Dolan M, Shearer G. Limiting dilution analysis of interleukin-2-producing T cells responsive to recall and alloantigens in human immunodeficiency virus-infected and uninfected individuals. Eur J Immunol 1993;23(2): p412-7.
118. Smith K, Skelton H, Heimer W, Baxter D, Angritt P, Frisman D, et al. Melanocytic activation in HIV-1 disease: HMB-45 staining in common acquired nevi. Military Medical Consortium for the Advancement of Retroviral Research. J Am Acad Dermatol 1993;29(4): p539-44.
119. Smith K, Skelton H, Hawks C, Yeager J, Wagner K. Concurrent HPV-16 infection of the nipple and perianal area in an HIV-1+ patient. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Int J Dermatol 1993;32(9): p664-7.
120. Smith K, Skelton H, Yeager J, Angritt P, Wagner K. Cutaneous neoplasms in a military population of HIV-1-positive patients. Military Medical Consortium for the Advancement of Retroviral Research. J Am Acad Dermatol 1993;29(3): p400-6.
121. Smith K, Skelton H, Vogel P, Yeager J, Baxter D, Wagner K. Exaggerated insect bite reactions in patients positive for HIV. Military Medical Consortium for the Advancement of Retroviral Research. J Am Acad Dermatol 1993;29(2 Pt 1): p269-72.
122. Smith K, Skelton H, Yeager J, Angritt P, Wagner K. Histologic features of foreign body reactions in patients infected with human immunodeficiency virus type 1. The Military Medical Consortium for Applied Retroviral Research. J Am Acad Dermatol 1993;28(3): p470-6.
123. Smith K, Skelton H, Yeager J, Angritt P, Frisman D, Wagner K, et al. Histopathologic and immunohistochemical findings associated with inflammatory dermatoses in human immunodeficiency virus type 1 disease and their correlation with Walter Reed stage. Military Medical Consortium for Applied Retroviral Research. J Am Acad Dermatol 1993;28(2 Pt 1): p174-84.
124. Smith K, Skelton H, Yeager J, Baxter D, Angritt P, Johnson S, et al. Clinical features of inflammatory dermatoses in human immunodeficiency virus type 1 disease and their correlation with Walter Reed stage. Military Medical Consortium for Applied Retroviral Research. J Am Acad Dermatol 1993;28(2 Pt 1): p167-73.
125. Stashower M, Yeager J, Smith K, Skelton H, Wagner K. Cimetidine as therapy for treatment-resistant psoriasis in a patient with acquired immunodeficiency syndrome. Arch Dermatol 1993;129(7): p848-50.

126. Vogel P, Smith K, Skeleton H, Cuozzo D, Wagner K. Verrucous lesions of herpes simplex in HIV-1+ patients. Military Medical Consortium for the Advancement of Retroviral Research. Int J Dermatol 1993;32(9): p680-2.
127. Warner R, Mathis R, Weston M, Bigbee L, Hendrix C, Lucey D. Estimates of human immunodeficiency virus (HIV) incidence and trends in the US Air Force. Vaccine 1993;11(5): p534-7.
128. Weiss P, Kennedy C, Wallace M, Nguyen M, Oldfield E. Medication costs associated with the care of HIV-infected patients. Clin Ther 1993;15(5): p912-6.
129. Wong M, Warren R, Anderson S, Dolan M, Hendrix C, Blatt S, et al. Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects. J Infect Dis 1993;168(6): p1523-7.
130. Biselli R, Loomis L, Del BV, Burke D, Redfield R, Birx D. Immunization of HIV-infected patients with rgp160: modulation of anti-rgp120 antibody spectrotype. J Acquir Immune Defic Syndr 1994;7(10): p1016-24.
131. Blatt S, Dolan M, Hendrix C, Melcher G. Legionnaires' disease in human immunodeficiency virus-infected patients: eight cases and review. Clin Infect Dis 1994;18(2): p227-32.
132. Clerici M, Sarin A, Coffman R, Wynn T, Blatt S, Hendrix C, et al. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci U S A 1994;91(25): p11811-5.
133. Clerici M, Wynn T, Berzofsky J, Blatt S, Hendrix C, Sher A, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994;93(2): p768-75.
134. Cowan D, Brundage J, Pomerantz R. The incidence of HIV infection among men in the United States Army Reserve Components, 1985-1991. AIDS 1994;8(4): p505-11.
135. Cowan D, Brundage J, Pomerantz R. HIV infection among women in the Army Reserve Components. J Acquir Immune Defic Syndr 1994;7(2): p171-6.
136. Hendrix C, Flexner C, Szebeni J, Kuwahara S, Pennypacker S, Weinstein J, et al. Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1994;38(5): p1036-40.
137. Japour A, Fiscus S, Arduino J, Mayers D, Reichelderfer P, Kuritzkes D. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994;32(9): p2291-4.
138. Mascola J, Louwagie J, McCutchan F, Fischer C, Hegerich P, Wagner K, et al. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis 1994;169(1): p48-54.
139. Mayers D, Japour A, Arduino J, Hammer S, Reichman R, Wagner K, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob Agents Chemother 1994;38(2): p307-14.
140. Musser J, Kapur V, Peters J, Hendrix C, Drehner D, Gackstetter G, et al. Real-time molecular epidemiologic analysis of an outbreak of Streptococcus pyogenes invasive disease in US Air Force trainees. Arch Pathol Lab Med 1994;118(2): p128-33.
141. Rusnak J, Butzin C, McGlasson D, Blatt S. False-positive rapid plasma reagin tests in human immunodeficiency virus infection and relationship to anti-cardiolipin antibody and serum immunoglobulin levels. J Infect Dis 1994;169(6): p1356-9.
142. Sarin A, Clerici M, Blatt S, Hendrix C, Shearer G, Henkart P. Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. J Immunol 1994;153(2): p862-72.

143. Scinicariello F, Dolan M, Nedelcu I, Tyring S, Hilliard J. Occurrence of human papillomavirus and p53 gene mutations in Kaposi's sarcoma. Virology 1994;203(1): p153-7.
144. Smith K, Skelton H, Yeager J, Ledsky R, McCarthy W, Baxter D, et al. Cutaneous findings in HIV-1-positive patients: a 42-month prospective study. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol 1994;31(5 Pt 1): p746-54.
145. Smith K, Wagner K, Yeager J, Skelton H, Ledsky R. Staphylococcus aureus carriage and HIV-1 disease: association with increased mucocutaneous infections as well as deep soft-tissue infections and sepsis. Arch Dermatol 1994;130(4): p521-2.
146. Smith K, Skelton H, Drabick J, McCarthy W, Ledsky R, Wagner K. Hypereosinophilia secondary to immunodysregulation in patients with HIV-1 disease. Arch Dermatol 1994;130(1): p119-21.
147. Vahey M, Birx D, Michael N, Burke D, Redfield R. Assessment of gag DNA and genomic RNA in peripheral blood mononuclear cells in HIV-infected patients receiving intervention with a recombinant gp 160 subunit vaccine in a phase I study. AIDS Res Hum Retroviruses 1994;10(6): p649-54.
148. Wallace M, Hooper D, Graves S, Malone J. Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine 1994;12(13): p1222-4.
149. Anderson D, De NJ, Zhao F, Vahey M, Lane J, Nau M, et al. Sampling lymph node content of human immunodeficiency virus type 1 nucleic acids and p24 antigen by fine-needle aspiration in early-stage patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 Suppl 2:S57-61.
150. Blatt S, McCarthy W, Bucko-Krasnicka B, Melcher G, Boswell R, Dolan J, et al. Multivariate models for predicting progression to AIDS and survival in human immunodeficiency virus-infected persons. J Infect Dis 1995;171(4): p837-44.
151. Brodine S, Mascola J, Weiss P, Ito S, Porter K, Artenstein A, et al. Detection of diverse HIV-1 genetic subtypes in the USA. Lancet 1995;346(8984): p1198-9.
152. Brown A, Lane J, Wagner K, Zhou S, Chung R, Ray K, et al. Rates of p24 antigenemia and viral isolation in comparable white and black HIV-infected subjects. Military Medical Consortium for Applied Retroviral Research. AIDS 1995;9(4): p325-8.
153. Brown A, Vahey M, Zhou S, Chung R, Ruiz N, Hofheinz D, et al. Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. The RV43 Study Group. J Infect Dis 1995;172(4): p1091-5.
154. Buckheit R, Fliakas-Boltz V, Yeagy-Bargo S, Weislow O, Mayers D, Boyer P, et al. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology 1995;210(1): p186-93.
155. Dolan M, Clerici M, Blatt S, Hendrix C, Melcher G, Boswell R, et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995;172(1): p79-87.
156. Gambel J, Brown A, Drabick J, Petruccelli B, Brundage J. Risk of late human immunodeficiency virus type 1 seroconversion in United States soldiers whose initial screening tests were reactive. Transfusion 1995;35(10): p886-7.
157. Hendrix C. Consideration of the prevalence of cytomegalovirus retinitis significantly alters the assessment of a serum cytomegalovirus DNA test. J Infect Dis 1995;171(6): p1688-90.
158. Kimberlin D, Spector S, Hill E, Biron K, Hay A, Mayers D, et al. Assays for antiviral drug resistance. Antiviral Res 1995;26(4): p403-13.

159. Levin L, Peterman T, Renzullo P, Lasley-Bibbs V, Shu X, Brundage J, et al. HIV-1 seroconversion and risk behaviors among young men in the US army. The Seroconversion Risk Factor Study Group. Am J Public Health 1995;85(11): p1500-6.
160. Lindstrom J, Smith K, Skelton H, Redfield R, Alving B, Wagner K, et al. Increased anticardiolipin antibodies associated with the development of anetoderma in HIV-1 disease. Military Medical Consortium for the Advancement of Retroviral research (MMCARR). Int J Dermatol 1995;34(6): p408-15.
161. Loomis L, Deal C, Kersey K, Burke D, Redfield R, Birx D. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(1): p13-26.
162. Malone J, Wallace M, Hendrick B, La RA, Tonon E, Brodine S, et al. Syphilis and neurosyphilis in a human immunodeficiency virus type-1 seropositive population: evidence for frequent serologic relapse after therapy. Am J Med 1995;99(1): p55-63.
163. Mayers D, Mikovits J, Joshi B, Hewlett I, Estrada J, Wolfe A, et al. Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains. Proc Natl Acad Sci U S A 1995;92(1): p215-9.
164. Mellors J, Bazmi H, Schinazi R, Roy B, Hsiou Y, Arnold E, et al. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother 1995;39(5): p1087-92.
165. Michael N, Mo T, Merzouki A, O'Shaughnessy M, Oster C, Burke D, et al. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol 1995;69(3): p1868-77.
166. Newton J, Tasker S, Bone W, Oldfield E, Olson P, Nguyen M, et al. Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection. AIDS 1995;9(11): p1286-7.
167. Nguyen M, Weiss P, Wallace M. Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1995;9(6): p573-5.
168. Oldfield E. Albendazole: new hope for treatment of microsporidiosis in AIDS. Am J Gastroenterol 1995;90(1): p159-60.
169. Ratto S, Sitz K, Scherer A, Manca F, Loomis L, Cox J, et al. Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients. J Infect Dis 1995;171(6): p1420-30.
170. Renzullo P, McNeil J, Wann Z, Burke D, Brundage J. Human immunodeficiency virus type-1 seroconversion trends among young adults serving in the United States Army, 1985-1993. United States Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(2): p177-85.
171. Smith K, Skelton H, Chu W, Yeager J, Angritt P, Wagner K. Decreased CD7 expression in cutaneous infiltrates of HIV-1+ patients. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Am J Dermatopathol 1995;17(6): p564-9.
172. Smith K, Skelton H, Yeager J, Ruiz N, Wagner K. Metronidazole for eosinophilic pustular folliculitis in human immunodeficiency virus type 1-positive patients. Arch Dermatol 1995;131(9): p1089-91.
173. Smith K, Skelton H, Ruiz N, Laskin W, Wagner K. Malignant lymphoma of soft tissue in an HIV-1+ patient. A rare site for primary malignant lymphoma with implications for treatment. Military Medical Consortium for the Advancement of Retroviral Research. Am J Dermatopathol 1995;17(4): p403-6.

174. Smith K, Skelton H, Wagner K. Pathogenesis of HIV-1 disease. Int J Dermatol 1995;34(5): p308-18.
175. Smith K, Skelton H, Yeager J, Wagner K. Cutaneous thrombosis in human immunodeficiency virus type 1-positive patients and cytomegalovirus viremia. Arch Dermatol 1995;131(3): p357-8.
176. Warren R, Wong M, Melcher G, Blatt S, Zapiola I, Bouzas M, et al. Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression. Clin Diagn Lab Immunol 1995;2(4): p400-3.
177. Warren R, Wong M, Melcher G, Blatt S, Cahn P, Perez H, et al. Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates. J Clin Microbiol 1995;33(2): p481-3.
178. Weiss P, Wallace M, Oldfield E, O'Brien J, Janoff E. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1995;171(5): p1217-22.
179. Welch M, Smith K, Skelton H, Turiansky G, Frisman D, Wagner K. Inflammatory linear verrucous epidermal nevus in patients with positive results of tests for human immunodeficiency virus 1. Cutis 1995;55(6): p365-8.
180. Wong M, Dolan M, Lattuada C, Regnery R, Garcia M, Mokulis E, et al. Neuroretinitis, aseptic meningitis, and lymphadenitis associated with Bartonella (Rochalimaea) henselae infection in immunocompetent patients and patients infected with human immunodeficiency virus type 1. Clin Infect Dis 1995;21(2): p352-60.
181. Artenstein A, Ohl C, Van CT, Hegerich P, Mascola J. Transmission of HIV-1 subtype E in the united states. JAMA 1996;276(2): p99-100.
182. Brown A, Brundage J, Tomlinson J, Burke D. The U.S. Army HIV testing program: the first decade. Mil Med 1996;161(2): p117-22.
183. Chougnet C, Wynn T, Clerici M, Landay A, Kessler H, Rusnak J, et al. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis 1996;174(1): p46-53.
184. Clerici M, Sarin A, Berzofsky J, Landay A, Kessler H, Hashemi F, et al. Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin. AIDS 1996;10(6): p603-11.
185. Dannenberg A, McNeil J, Brundage J, Brookmeyer R. Suicide and HIV infection. Mortality follow-up of 4147 HIV-seropositive military service applicants. JAMA 1996;276(21): p1743-6.
186. Flemmer M, Oldfield E, Melek B. Acute retroviral disease masquerading as bacterial sepsis: the "bands" play on. South Med J 1996;89(3): p354-5.
187. Flemmer M, Oldfield E. AIDS diarrhea: new kid on the paraffin-block. Am J Gastroenterol 1996;91(2): p402-3.
188. Hickey T, Blair P, Perfetto S, Smoot D, Wagner K, St LD, et al. Intact antigen receptor-mediated calcium signals in patients with early stage HIV-1 infection. J Immunol 1996;156(10): p4012-7.
189. Kaushal S, La RV, Gartner S, Kessler S, Perfetto S, Yu Z, et al. Exposure of human CD34+ cells to human immunodeficiency virus type 1 does not influence their expansion and proliferation of hematopoietic progenitors in vitro. Blood 1996;88(1): p130-7.
190. Levine B, Mosca J, Riley J, Carroll R, Vahey M, Jagodzinski L, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996;272(5270): p1939-43.

191. Mascola J, Snyder S, Weislow O, Belay S, Belshe R, Schwartz D, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173(2): p340-8.
192. Meier P, Stephan K, Blatt S. Cytomegalovirus polyradiculopathy in HIV-infected patients. J Gen Intern Med 1996;11(1): p47-9.
193. Nguyen M, Weiss P, La BR, Miller L, Oldfield E, Wallace M. Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans. AIDS 1996;10(14): p1745-7.
194. Olson P, Wallace M, Grillo M, Rossetti R, Miller L. Lack of utility of routine chest radiographs in HIV-infected patients. AIDS 1996;10(4): p446-7.
195. Shafer R, Winters M, Mayers D, Japour A, Kuritzkes D, Weislow O, et al. Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group. J Clin Microbiol 1996;34(7): p1849-53.
196. Sharma P, Chatis P, Dogon A, Mayers D, McCutchan F, Page C, et al. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay. Virology 1996;223(2): p365-9.
197. Simberkoff M, Hartigan P, Hamilton J, Day P, Diamond G, Dickinson G, et al. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11(2): p142-50.
198. Skillman D, Malone J, Decker C, Wagner K, Mapou R, Liao M, et al. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity. J Infect Dis 1996;173(5): p1107-14.
199. Smith K, Skelton H, Hilyard E, Hadfield T, Moeller R, Tuur S, et al. Bacillus piliformis infection (Tyzzer's disease) in a patient infected with HIV-1: confirmation with 16S ribosomal RNA sequence analysis. J Am Acad Dermatol 1996;34(2 Pt 2): p343-8.
200. Smith K, Skelton H, De RD, Sperling L, Yeager J, Wagner K, et al. Clinical and histopathologic features of hair loss in patients with HIV-1 infection. J Am Acad Dermatol 1996;34(1): p63-8.
201. Wallace M, Moss R, Beecham H, Grace C, Hersh E, Peterson E, et al. Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(4): p358-62.
202. Wong M, Dolan M, Kozlow E, Doe R, Melcher G, Burke D, et al. Patterns of virus burden and T cell phenotype are established early and are correlated with the rate of disease progression in human immunodeficiency virus type 1-infected persons. J Infect Dis 1996;173(4): p877-87.
203. Artenstein A, Van CT, Sitz K, Robb M, Wagner K, Veit S, et al. Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical information. J Infect Dis 1997;175(2): p265-71.
204. Blair P, Boise L, Perfetto S, Levine B, McCrary G, Wagner K, et al. Impaired induction of the apoptosis-protective protein Bcl-xL in activated PBMC from asymptomatic HIV-infected individuals. J Clin Immunol 1997;17(3): p234-46.
205. Carroll R, Riley J, Levine B, Feng Y, Kaushal S, Ritchey D, et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 1997;276(5310): p273-6.

206. Ellis R, Hsia K, Spector S, Nelson J, Heaton R, Wallace M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997;42(5): p679-88.
207. Ellis R, Deutsch R, Heaton R, Marcotte T, McCutchan J, Nelson J, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997;54(4): p416-24.
208. Evans J, Nims T, Cooley J, Bradley W, Jagodzinski L, Zhou S, et al. Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997;175(4): p795-800.
209. Le T, Tribble D, Zhou S, Malone L, Chung R, Rusnak J, et al. Clinical significance of discordant CD4 count and CD4 percentage in HIV-infected individuals. AIDS 1997;11(11): p1395-6.
210. Levine B, Bernstein W, Craighead N, Thompson C, Lindsten T, St LD, et al. Ex vivo replicative potential of adult human peripheral blood CD4+ T cells. Transplant Proc 1997;29(4): p2028.
211. Levine B, Bernstein W, Connors M, Craighead N, Lindsten T, Thompson C, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159(12): p5921-30.
212. Lucey D, Pinto L, Bethke F, Rusnak J, Melcher G, Hashemi F, et al. In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol 1997;4(1): p43-8.
213. Marschner I, Mayers D, Erice A, Smeaton L, Johnson V, Richman D, et al. Standardized peripheral blood mononuclear cell culture assay for zidovudine susceptibility testing of clinical human immunodeficiency virus type 1 isolates: effect of reducing the numbers of replicates and concentrations. J Clin Microbiol 1997;35(3): p756-8.
214. Mayers D. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med 1997;102(5B): p70-5.
215. McDonald R, Mayers D, Chung R, Wagner K, Ratto-Kim S, Birx D, et al. Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function. J Virol 1997;71(3): p1871-9.
216. Moss R, Trauger R, Giermakowska W, Turner J, Wallace M, Jensen F, et al. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14(4): p343-50.
217. Moss R, Giermakowska W, Lanza P, Turner J, Wallace M, Jensen F, et al. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects. Viral Immunol 1997;10(4): p221-8.
218. Perfetto S, Hickey T, Blair P, Maino V, Wagner K, Zhou S, et al. Measurement of CD69 induction in the assessment of immune function in asymptomatic HIV-infected individuals. Cytometry 1997;30(1): p1-9.
219. Riley J, Carroll R, Levine B, Bernstein W, St LD, Weislow O, et al. Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. J Immunol 1997;158(11): p5545-53.
220. Rodriguez R, Dayhoff D, Chang G, Cassol S, Birx D, Artenstein A, et al. Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15(1): p49-53.
221. Shinohara Y, Tasker S. Successful use of boric acid to control azole-refractory Candida vaginitis in a woman with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16(3): p219-20.

222. Smith K, Skelton H, Tuur S, Yeager J, Decker C, Wagner K. Increased cutaneous toxicity to ionizing radiation in HIV-positive patients. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Int J Dermatol 1997;36(10): p779-82.
223. Smith K, Skelton H, Yeager J, Tuur S, Angritt P, Wagner K. Histopathologic features seen in cutaneous photoeruptions in HIV-positive patients. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Int J Dermatol 1997;36(10): p745-53.
224. Smith K, Skelton H, Yeager J, Ledsky R, Ng T, Wagner K. Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Clin Exp Dermatol 1997;22(3): p118-23.
225. Smith K, Nelson A, Skelton H, Yeager J, Wagner K. Pityriasis lichenoides et varioliformis acuta in HIV-1+ patients: a marker of early stage disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Int J Dermatol 1997;36(2): p104-9.
226. Smith K, Skelton H, Turiansky G, Wagner K. Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol 1997;36(2 Pt 1): p239-42.
227. Smith K, Skelton H, Yeager J, Lee R, Wagner K. Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation. Dermatology 1997;195(4): p353-8.
228. Smith K, Skelton H, Nelson A, Wagner K, Hackley B. Preservation of allergic contact dermatitis to poison ivy (urushiol) in late HIV disease. The implications and relevance to immunotherapy with contact allergens. Dermatology 1997;195(2): p145-9.
229. Wallace M, Heaton R, McCutchan J, Malone J, Velin R, Nelson J, et al. Neurocognitive impairment in human immunodeficiency virus infection is correlated with sexually transmitted disease history. Sex Transm Dis 1997;24(7): p398-401.
230. Gardner L, Harrison S, Hendrix C, Blatt S, Wagner K, Chung R, et al. Size and duration of zidovudine benefit in 1003 HIV-infected patients: U.S. Army, Navy, and Air Force natural history data. Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17(4): p345-53.
231. Levine B, Cotte J, Small C, Carroll R, Riley J, Bernstein W, et al. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998;7(5): p437-48.
232. Martin M, Carrington M, Dean M, O'Brien S, Sheppard H, Wegner S, et al. CXCR4 polymorphisms and HIV-1 pathogenesis. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19(4): p430.
233. Moss R, Wallace M, Lanza P, Giermakowska W, Jensen F, Theofan G, et al. In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune). Clin Diagn Lab Immunol 1998;5(3): p308-12.
234. Mummidi S, Ahuja S, Gonzalez E, Anderson S, Santiago E, Stephan K, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998;4(7): p786-93.
235. Oldfield E, Fessel W, Dunne M, Dickinson G, Wallace M, Byrne W, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis 1998;26(3): p611-9.

236. Perfetto S, Malone J, Hawkes C, McCrary G, August B, Zhou S, et al. CD38 expression on cryopreserved CD8+ T cells predicts HIV disease progression. Cytometry 1998;33(2): p133-7.
237. Pericle F, Pinto L, Hicks S, Kirken R, Sconocchia G, Rusnak J, et al. HIV-1 infection induces a selective reduction in STAT5 protein expression. J Immunol 1998;160(1): p28-31.
238. Polhemus M, Aronson N. Persistent nephrolithiasis after discontinuation of indinavir therapy. Clin Infect Dis 1998;27(6): p1536-7.
239. Tasker S, O'Brien W, Treanor J, Weiss P, Olson P, Kaplan A, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 1998;16(9-10): p1039-42.
240. Wegner S, Ehrenberg P, Chang G, Dayhoff D, Sleeker A, Michael N. Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem 1998;273(8): p4754-60.
241. Brodine S, Shaffer R, Starkey M, Tasker S, Gilcrest J, Louder M, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999;131 (7): p502-6.
242. Cox J, Garner R, Redfield R, Aronson N, Davis C, Ruiz N, et al. Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine. AIDS Res Hum Retroviruses 1999;15(9): p847-54.
243. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda R, Catano G, et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci U S A 1999;96(21): p12004-9.
244. Janoff E, Tasker S, Stevenson M, Rubins J, O'Brien J, Utz G, et al. Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. AIDS Res Hum Retroviruses 1999;15(9): p837-45.
245. Moss R, Wallace M, Giermakowska W, Webb E, Savary J, Chamberlin-Brandt C, et al. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. J Infect Dis 1999;180 (3): p641-8.
246. Ratto-Kim S, Sitz K, Garner R, Kim J, Davis C, Aronson N, et al. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. J Infect Dis 1999;179(2): p337-44.
247. Storey D, Dolan M, Anderson S, Meier P, Walter E. Seminal plasma RANTES levels positively correlate with seminal plasma HIV-1 RNA levels. AIDS 1999;13 (15): p2169-71.
248. Tasker S, Treanor J, Paxton W, Wallace M. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131 (6): p430-3.
249. Vahey M, Nau M, Barrick S, Cooley J, Sawyer R, Sleeker A, et al. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol 1999;37 (8): p2533-7.
250. Williams S, Flanigan T, Artenstein A, Van CT, Smith D, Mayer K, et al. CCR5 genotype and human immunodeficiency virus (HIV)-specific mucosal antibody in seronegative women at high risk for HIV infection. J Infect Dis 1999;179(5): p1310-2.
251. Birx D, Loomis-Price L, Aronson N, Brundage J, Davis C, Deyton L, et al. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis 2000;181(3): p881-9.

252. Hertogs K, Bloor S, De VV, van DEC, Dehertogh P, van CA, et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother 2000;44(3): p568-73.
253. Maino V, Suni M, Wormsley S, Carlo D, Wallace M, Moss R. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. AIDS Res Hum Retroviruses 2000;16(6): p539-47.
254. More D, O'Brien K, Walter E. Utility of an HIV-1 RNA assay in the diagnosis of acute retroviral syndrome. South Med J 2000;93(10): p1004-6.
255. Moss R, Giermakowska W, Wallace M, Savary J, Jensen F, Carlo D. Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen. AIDS 2000;14 (16): p2475-8.
256. Moss R, Giermakowska W, Wallace M, Savary J, Jensen F, Carlo D. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune). Clin Diagn Lab Immunol 2000;7 (5): p724-7.
257. Moss R, Webb E, Giermakowska W, Jensen F, Savary J, Wallace M, et al. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant. J Acquir Immune Defic Syndr 2000;24 (3): p264-9.
258. Moss R, Giermakowska W, Diveley J, Savary J, Wallace M, Maigetter R, et al. CXCR4 and CCR5 expression on CD4+ T cells in vivo and HIV-1 antigen beta-chemokine production in vitro after treatment with HIV-1 immunogen (REMUNE). J Hum Virol 2000;3 (1): p44-9.
259. Mummidi S, Bamshad M, Ahuja S, Gonzalez E, Feuillet P, Begum K, et al. Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. J Biol Chem 2000; 275 (25): p18946-61.
260. Napravnik S, Royce R, Walter E, Lim W. HIV-1 infected women and prenatal care utilization: barriers and facilitators. AIDS Patient Care STDS 2000; 14 (8): p411-20.
261. Pinto L, Williams M, Dolan M, Henkart P, Shearer G. Beta-chemokines inhibit activation-induced death of lymphocytes from HIV-infected individuals. Eur J Immunol 2000;30 (7): p2048-55.
262. Pinto L, Blazevic V, Patterson B, MacTrubey C, Dolan M, Shearer G. Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation. J Virol 2000;74 (10): p4505-11.
263. Pinto L, Blazevic V, Shearer G, Patterson B, Dolan M. Alloantigen-induced anti-HIV activity occurs prior to reverse transcription and can be generated by leukocytes from HIV-infected individuals. Blood 2000; 95 (5): p1875-6.
264. Wallace M, Brann O. Gastrointestinal manifestations of hiv infection [In Process Citation]. Curr Gastroenterol Rep 2000; 2(4): p283-93.
265. Walter E, Gilliam B, Delmar J, Spooner K, Morris J, Aronson N, et al. Clinical implications of identifying non-B subtypes of human immunodeficiency virus type 1 infection. Clin Infect Dis 2000;31 (3): p798-802.
266. Wegner S, Brodine S, Mascola J, Tasker S, Shaffer R, Starkey M, et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 2000;14(8): p1009-15.

267. Aronson N, Cheney C, Rholl V, Burris D, Hadro N. Biliary giardiasis in a patient with human immunodeficiency virus. J Clin Gastroenterol 2001;33(2): p167-70.
268. Booth-Kewley S, Andrews A, Shaffer R, Gilman P, Minagawa R, Brodine S. One-year follow-up evaluation of the sexually transmitted diseases/human immunodeficiency virus intervention program in a marine corps sample. Mil Med 2001;166(11): p987-95.
269. Booth-Kewley S, Gilman P, Shaffer R, Brodine S. Evaluation of a sexually transmitted disease/human immunodeficiency virus prevention train-the-trainer program. Mil Med 2001;166(4): p304-10.
270. Boyer C, Shafer M, Shaffer R, Brodine S, Ito S, Yniguez D, et al. Prevention of sexually transmitted diseases and HIV in young military men: evaluation of a cognitive-behavioral skills-building intervention. Sex Transm Dis 2001;28(6): p349-55.
271. Brown A, Dolan M, Michael N, Zhou S, Perfetto S, Hawkes C, et al. Clinical prognosis of patients with early-stage human immunodeficiency virus (HIV) disease: contribution of HIV-1 RNA and T lymphocyte subset quantitation. Mil Med 2001;166(7): p571-6.
272. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A 2001;98(9): p5199-204.
273. Grene E, Pinto L, Landay A, Kessler H, Anderson S, Dolan M, et al. Anti-CCR5 antibodies in sera of HIV-positive individuals. Hum Immunol 2001;62(2): p143-5.
274. Harrigan P, Montaner J, Wegner S, Verbiest W, Miller V, Wood R, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001;15(13): p1671-7.
275. Mangano A, Gonzalez E, Dhanda R, Catano G, Bamshad M, Bock A, et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001;183(11): p1574-85.
276. Moss R, Giermakowska W, Wallace M, Jensen F, Maigetter R, Carlo D. Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen. Clin Exp Immunol 2001;124(2): p248-54.
277. Pinto L, Blazevic V, Anderson S, Venzon D, Trubey C, Rowe T, et al. Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects. J Infect Dis 2001;183(7): p1000-8.
278. Sparling J, Norwood C, Turiansky G, Oster C. Diagnostic and therapeutic dilemmas of a large scrotal lesion in an AIDS patient. AIDS Read 2001;11(1): p43-7.
279. Wallace M, Nelson J, McCutchan J, Wolfson T, Grant I. Symptomatic HIV seroconverting illness is associated with more rapid neurological impairment. Sex Transm Infect 2001;77(3): p199-201.
280. Wallace M, Tasker S, Shinohara Y, Hill H, Chapman G, Miller L. The changing economics of HIV care. AIDS Patient Care STDS 2001;15(1): p25-9.
281. Wallace M, Persing D, McCutchan J, Magara J, Nelson J, Heaton R, et al. Bartonella henselae serostatus is not correlated with neurocognitive decline in HIV infection. Scand J Infect Dis 2001;33(8): p593-5.
282. Booth-Kewley S, Shaffer R, Minagawa R, Brodine S. Effectiveness of two versions of a sexually transmitted diseases/human immunodeficiency virus prevention program. Mil Med 2002;167(3): p254-9.
283. Booth-Kewley S, Minagawa R, Shaffer R, Brodine S. A behavioral intervention to prevent sexually transmitted diseases/human immunodeficiency virus in a Marine Corps sample. Mil Med 2002;167(2): p145-50.

284. Levine B, Bernstein W, Aronson N, Schlienger K, Cotte J, Perfetto S, et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8(1): p47-53.
285. Moss R, Wallace M, Steigbigel R, Morrison S, Giermakowska W, Nardo C, et al. Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination. Clin Exp Immunol 2002;128(2): p359-64.
286. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, Fraser S, Dolan MJ, Stephan KT, Michael NL, Jagodzinski LL, Vahey MT, Gilcrest JL, Tracy L, Milazzo MJ, Murphy DJ, Hertogs K, Larder BA, Birx DL. Long-term efficacy of routine access to antiretroviral resistance testsing in HIV-1-infecte patients: Results of the Clinical Efficacy of Resistance Testing (CERT) trial. Clin. Infect. Dis. 2004; 38:723-730.
287. Lin AL. Johnson DA. Stephan KT. Yeh CK. Alteration in salivary function in early HIV infection. Journal of Dental Research. 82(9):719-24, 2003 Sep.
288. O'Connell RJ. Merritt TM. Malia JA. VanCott TC. Dolan MJ. Zahwa H. Bradley WP. Branson BM. Michael NL. De Witt CC. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. Journal of Clinical Microbiology. 41(5):2153-5, 2003 May.
289. Gonzalez E. Rovin BH. Sen L. Cooke G. Dhanda R. Mummidi S. Kulkarni H. Bamshad MJ. Telles V. Anderson SA. Walter EA. Stephan KT. Deucher M. Mangano A. Bologna R. Ahuja SS. Dolan MJ. Ahuja SK. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proceedings of the National Academy of Sciences of the United States of America. 99(21):13795-800, 2002 Oct 15.
290. Brown AE. Dolan MJ. Michael NL. Zhou S. Perfetto SP. Hawkes C. Robb M. Lane J. Mayers D. McNeil JG. Malone JD. Garner R. Birx DL. RGP160 Phase IIA Vaccine Investigators. Clinical prognosis of patients with early-stage human immunodeficiency virus (HIV) disease: contribution of HIV-1 RNA and T lymphocyte subset quantitation. Military Medicine. 166(7):571-6, 2001 Jul.
291. Mangano A. Gonzalez E. Dhanda R. Catano G. Bamshad M. Bock A. Duggirala R. Williams K. Mummidi S. Clark RA. Ahuja SS. Dolan MJ. Bologna R. Sen L. Ahuja SK. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. Journal of Infectious Diseases. 183(11):1574-85, 2001 Jun 1.
292. Gonzalez E. Dhanda R. Bamshad M. Mummidi S. Geevarghese R. Catano G. Anderson SA. Walter EA. Stephan KT. Hammer MF. Mangano A. Sen L. Clark RA. Ahuja SS. Dolan MJ. Ahuja SK. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proceedings of the National Academy of Sciences of the United States of America. 98(9):5199-204, 2001 Apr 24.
293. Pinto LA. Blazevic V. Anderson SA. Venzon DJ. Trubey CM. Rowe T. Katz JM. Liewehr D. Dolan MJ. Shearer GM. Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects. Journal of Infectious Diseases. 183(7):1000-8, 2001 Apr 1.
294. Grene E. Pinto LA. Landay AL. Kessler HA. Anderson SA. Dolan MJ. Shearer GM. Anti-CCR5 antibodies in sera of HIV-positive individuals. Human Immunology. 62(2):143-5, 2001 Feb.
295. Crum NF, Wallace MR, Stephan K, Blazes DL, Aronson N, Tasker SA, Thomas AG, Wegner S, Casper C, Wald A, Corey L, Brodine SK. Correlates of Human Herpesvirus-8 seropositivity among U.S. military members recently infected with human immunodeficiency virus. Sexually Transmitted Diseases, 2003; 30:713-8.

296. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, Kulkarni H, Bamshad MJ, Telles V, Anderson SA, Walter EA, Stephan KT, Deucher M, Mangano A, Bologna R, Ahuja SS, Dolan MJ, Ahuja SK. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13795-800. Epub 2002 Oct 8.
297. Agan BK, Dolan MJ. Laboratory diagnosis of Bartonella infections. Clin Lab Med. 2002 Dec;22(4):937-62. Review.
298. O'Connell RJ, Merritt TM, Malia JA, VanCott TC, Dolan MJ, Zahwa H, Bradley WP, Branson BM, Michael NL, De Witt CC. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol. 2003 May;41(5):2153-5.
299. Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, Tamminga CL, Stephan KT, Aronson NE, Fraser SL, Wallace MR, Wegner SA, Mascola JR, McCutchan FE. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003 Nov 21;17(17):2521-7.
300. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, Fraser S, Dolan MJ, Stephan KT, Michael NL, Jagodzinski LL, Vahey MT, Gilcrest JL, Tracy L, Milazzo MJ, Murphy DJ, McKenna P, Hertogs K, Rinehart A, Larder B, Birx DL; RV-125 Centers for Education and Research on Therapeutics Study Team. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis. 2004 Mar 1;38(5):723-30. Epub 2004 Feb 6.
301. Kijak GH, Currier JR, Tovanabutra S, Cox JH, Michael NL, Wegner SA, Birx DL, McCutchan FE. Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance. AIDS Rev. 2004 Jan-Mar;6(1):54-60. Review.
302. Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, Dolan MJ, Chougnet C, Lifson JD, Shearer GM. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood. 2005 Mar 15;105(6):2458-64. Epub 2004 Dec 7.
303. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'connell RJ, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ, Ahuja SK. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005 Mar 4;307(5714):1434-40. Epub 2005 Jan 6.